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Preface 
Tissue engineering is an interdisciplinary field based on the creation of new tissues and 
organs. Ideal biomaterials for bone tissue regeneration must possess appropriate 
chemical, biochemical and biophysical properties. It is well-known that bone 
regeneration depends on several parameters, such as material properties, chemical and 
bioactive stimuli, and cells. This thesis provides an overview of innovative strategies in 
the field of bone tissue regeneration. In particular, this thesis concerns the advantages of 
using scaffolds and injectable biomaterials in tissue engineering for restorative and 
regenerative purposes. Recent findings (across the past decade) in stem cell biology and 
tissue engineering suggest new approaches for bone regeneration. In fact, stem cells have 
the potential to self-renew and give rise to a variety of cell types to ensure tissue 
regeneration. In this context,  considerable attention has been given to device preparation 
using different approaches, therein conferring distinctive features on composite materials 
for bone repair. In fact, it is possible to introduce technologies in the biomedical field, 
allowing biomaterials with specific features such as specific injectability, architecture, 
geometry, porosity and interconnectivity to be obtained. These properties are critical for 
biological and mechanical performance. The principle idea behind this project is to 
develop new types of bioactive materials in order to repair bone defects associated with 
diseases such as osteoporosis with a focus on the functional use of “soft” materials for 
bone regeneration. This thesis explores the study, optimization and evaluation of systems 
that support bone regeneration by increasing the production of osteoblasts in osteoporotic 
sites as a new frontier for osteoporosis treatment and more specifically ,the development 
of porous composite scaffolds based on chitosan for bone regeneration using two 
different approaches. The study of these scaffolds is based on the fabrication of calcium 
phosphate injectable materials functionalized with ionic liquids using the sol-gel 
technique to promote bone regeneration and to prevent microbial infection and 
inflammation. Chapter I focuses on the State of the Art, while Chapter II deals with the 
development of chitosan-based scaffolds bioactivated by osteoinductive signals (e.g. 
hydroxyapatite nanoparticles, BMP-2 peptide) for advanced bone tissue engineering. 
Scaffolds were prepared through a new foaming method by Dr. Demitri at University of 
Salento. The method is useful because it permits synthesizing semi-interpenetrating 
Chitosan-PEGDA scaffolds at different concentrations. Mechanical and morphological 
characterisations were evaluated, and the in vitro effect of bioactivated scaffolds on 
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cellular behaviour was determined by analysing their osteoinductive properties. Finally, 
in the last part of Chapter II, the evaluation of the in vitro effect of bioactivated chitosan 
scaffolds on the angiogenesis process is also reported. Chapter III describes the 
fabrication of injectable ionic liquid-hydroxyapatite-based biocomposites obtained via the  
sol-gel method, which allows work to be conducted at room temperature with thermo-
sensitive molecules. Most of the chapter is dedicated to the importance of the use of 
injectable materials for bone tissue regeneration with particular attention paid to the 
ability of ionic liquids to prevent and reduce microbial infections. Later, the chapter 
reports on the evaluation of the effects of these injectable gels on biological performance 
with a special focus on osteogenic and anti-inflammatory responses. From the beginning, 
this study involved the development, preparation and characterisation of biomaterials. 
Over time  the work has gained a new focus: evaluating the antimicrobial and 
osteoinductive properties of the proposed multifunctional injectable systems. Finally, 
Chapter IV includes conclusions and future perspectives. 
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CHAPTER I 
 
State of the art 
 
1.1 Bone tissue 
Bone comprises the majority of the skeleton and plays a key role in the body, both 
biomechanically and metabolically. There are three main functions associated with 
skeletal tissue: support, protection and calcium homeostasis. Indeed, the rigidity and 
hardness of bone maintains the shape of the body and supports it, permitting the transfer 
of muscular forces from one part of the body to another during normal movement. 
Moreover, bone exerts a pivotal function by protecting the soft tissue of cranial, thoracic 
and pelvic cavities. Bone contains minerals, which are a reserve for ions, especially 
calcium and are involved in the regulation of extracellular fluid composition. By weight, 
the bone matrix is composed of approximately 28% organic matter, 60% inorganic 
substance and the remaining 12% water or 38.4% organic matter, 37.7% mineral and 
23.9% water by volume [1]. The mineral composition is impure and includes 
hydroxyapatite, Ca10(PO4)6(OH)2, which contains carbonate, citrate, fluoride and 
strontium. The organic matrix consists of 90% collagen and about 10% non-collagenous 
proteins. From a mechanical point of view, the bone matrix is comparable to a composite 
material: the organic matrix is responsible for giving the toughness to bones, whereas the 
inorganic matrix has the function to stiffen and strengthen the bone [2]. In normal 
condition, a balance between resorption and oppositional processes characterises bone. In 
fact, bone cells are responsible of the processes of bone resorption, formation, and 
modelling. When an alteration in bone processes appears, osteoporosis and Paget’s 
disease occur [3]. 
 
1.2 Osteoporosis 
Osteoporosis is a debilitating, progressive, metabolic, systemic, chronic disease 
characterised by bone mass reduction and micro-architectural structure impairment in 
tissues. Osteoporosis can be primary (post-menopausal and senile) or secondary. The 
most common type of osteoporosis is primary osteoporosis, which affects more women 
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than men. Primary osteoporosis is characterised by a peak in bone mass density at about 
age 30. After this period, the rate of bone loss slowly increases, while the rate of bone 
building decreases. The thickness of the bones in early life as well as health, diet, and 
physical activity at all ages influence the development and progression of osteoporosis. In 
women, accelerated bone loss usually appears after monthly menstrual periods stop. Post-
menopausal osteoporosis is due to a reduction in oestrogen production (usually between 
the ages of 45 and 55). In men, gradual bone loss typically begins at about 45 to 50 years 
of age, when a man's production of testosterone slows down. Osteoporosis usually affects 
women at an earlier age than men, as they generally have lower bone mass. Secondary 
osteoporosis causes the same symptoms as primary osteoporosis but it occurs because of 
specific medical conditions, such as hyperparathyroidism, hyperthyroidism, or leukaemia. 
However, secondary osteoporosis can also occur as the consequence of pharmacological 
treatments with drugs that induce bone breakdown, such as oral or high-dose inhaled 
corticosteroids (long-term treatments), too high a dose of thyroid replacement, or 
aromatase inhibitors. In contrast to primary osteoporosis, secondary osteoporosis can 
occur at any age. 
Osteoporosis is defined as a “silent disease” because of the absence of apparent 
symptoms until a fracture occurs. It has been demonstrated that the bone loss is a silent 
and progressive process, in which the density and quality of the bone are greatly reduced 
(Figure 1), [4]. Osteoporosis disorder represents a growing problem in ageing people. It 
affects a large portion of the population, especially the elderly and postmenopausal 
women. Younger women, children and pregnant women can be affected as well. It has 
been noted that 1/3 of women and 1/5 of men are at risk for fractures resulting from 
osteoporosis. Indeed, the most common fractures associated with osteoporosis are at the 
hip, spine and wrist. At the time of writing, it’s estimated that more than 200,000,000 
people in the world suffer from this disease. In the United States and Europe alone, 
approximately 30% of all postmenopausal women have osteoporosis. At least 40% of 
women with osteoporosis and 15-30% of men experience one or more fragility fractures 
in their remaining lifetime [5]. An increasing proportion of the population going through 
the ageing process is responsible for a major increase in the osteoporosis incidence 
among postmenopausal women (Figure 2). Osteoporosis has a multifactorial aetiology 
and its clinical manifestation is connected to the complex relationship between 
environmental and genetic factors. Indeed, many elements, such as age related 
(epigenetic) changes, genetic predisposition and intrinsic factors induce an impairment of 
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bone regeneration and mechanical adaptation. The main risk factors besides age include 
the following: lifestyle, family history, female gender, hormonal status, long-term use of 
steroid medications, such as glucocorticoid, and the oestrogen deficiency that occurs with 
ageing. Oestrogen deficiency is especially problematic in the case of post-menopausal 
women. Indeed, lower oestrogen levels in the organism are one of the strongest risk 
factors for bone loss. Decades of research have underlined the effects of oestrogen on 
bone healing and maintenance through two different types of cells, osteoclasts and 
osteoblasts. It has been reported that oestrogen has a pivotal role in the modulation of 
bone metabolism, as a powerful modulator in this crucial process. Indeed, the deficiency 
in steroid hormone production is responsible for promoting higher resorption as 
compared to bone formation and therefore delays in fracture healing. Another 
consequence of the post-menopausal oestrogen level decrease is the loss of bone strength. 
The deficiency in this sex hormone also induces fatty bone marrow degeneration. 
Therefore, this imbalance facilitates adipogenic differentiation over osteogenic 
differentiation and is the basis of bone degeneration. It is well-known that the bone is 
dynamic tissue that undergoes a continuous physiological process of remodelling. Indeed, 
bone resorption, under normal conditions, is counterbalanced by bone formation in order 
to maintain the healthy function of the bone. There is a cross-talk between different kinds 
of cells in human bone: osteoblasts, osteoclasts, and osteocytes. Osteoblasts and 
osteocytes possess the role of building new bone and generating healthy tissue, 
meanwhile osteoclasts remove and break down old bone and reduce defects in the micro-
architecture of bone tissue. When an impairment of balance between bone resorption and 
formation occurs, osteoporotic pathology appears. Alterations in bone remodelling, which 
promote bone resorption over de novo synthesis, lead to diseases such as osteoporosis. 
The pathological condition of osteoporosis consists of changes in the physical properties 
of bone matrix and the imbalance causes a decreased bone mineral density (BMD). The 
osteoporotic bone is characterised by higher porosity and fragility than normal bone, 
making the bone more sensitive to fractures, among the most common, hip fractures. It 
has been demonstrated that the disorder can be localised in a specific osteoporotic site or 
can involve the entire skeleton with high impact trauma and bone fractures. The above 
leads to serious consequences in the health and life quality of patients and in healthcare 
costs. Epidemiological studies show that the diagnosis of the pathogenesis of 
osteoporosis is still difficult, due to the complexity of pathogenesis. This issue 
encourages the researchers to pay more attention to prevention, and the search for new 
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therapeutic strategies for the treatment of the disease. In this context, the engineering of 
complex bones built using several materials (porous scaffolds and injectable gels) 
combined with differentiation factors, and precursor cells, represents a useful tool for 
promoting bone tissue regeneration and preventing osteoporotic fractures. 
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Figure 1. Images of the reduction in osteoporotic bone density compared to healthy bone 
mass. 
 
 
 
 
Figure 2. Post-menopausal women affected by osteoporosis and the clinical 
consequences of spinal column shortening. 
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1.2.1 Current therapies for osteoporosis treatment 
There are several therapeutic targets for osteoporosis. The main goals of osteoporosis 
treatments are to reduce the loss of bone mass, to prevent bone fractures, and to treat 
clinical consequences and symptoms associated with the disease. It is well known that 
bone loss can be reduced also by building new bone or inhibiting osteoclasts, which leads 
to a breakdown of the old bone. There are many different approaches, including 
pharmacological therapy, physiotherapy interventions, and surgical treatment. However, 
many osteoporotic patients do not tolerate the currently available options, due to several 
side effects, as among them renal and gastrointestinal diseases associated with the 
administration of some conventional drugs. Clinically approved therapies to treat 
osteoporosis include oestrogen replacement therapy, the use of bisphosphonates (e.g., 
alendronate and zoledronic acid), the systemic use of parathyroid hormone (PHT), 
calcitonin and strontium ranelate, (not approved in the United States). Strontium ranelate 
is a first-line treatment for post-menopausal osteoporotic patients. The effectiveness of 
treatment with anti-osteoporotic drugs has been documented in a wide range of patient 
profiles varying by age, number of prevalent vertebral fractures, body mass index and 
family history of osteoporosis. Indeed, strontium ranelate, due to its double and 
simultaneous action mechanism, has the ability to increase bone formation by inhibiting 
or slowing the bone resorption process. It affects BMD, in addition to restoring bone 
turnover and osteoporotic fractures. The rebalancing in bone replacement is based on the 
improvement of bone geometry, cortical thickness, trabecular bone morphology and 
intrinsic tissue quality. Several controlled trials emphasize the importance and the 
efficiency of strontium ranelate in osteoporosis to reduce the risk of vertebral and hip 
fractures. However, its systemic administration has many limitations. Even though the 
drug possesses a wide spectrum of efficacy, high tolerance and safety, sometimes it can 
cause undesirable side effects (e.g. gastrointestinal disorders, venous thromboembolism, 
myocardial infarction) and low compliance at the site of interest. In this context, tissue 
engineering is a good approach to reducing problems associated with systemic 
administration. New controlled-release systems in osteoporotic centres can be developed. 
A modern approach is based on the combination and the synergistic use of suitable 
polymeric and/or ceramic structures (in terms of biocompatibility, biodegradability, 
chemical-physical, mechanical and biological properties), biomolecules and cells. A 
recent study suggested that 8.5% of patients reported low adherence to osteoporosis 
medications and 21.6% of them stopped their medication completely over the following 
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two years [6]. Therefore, there is a compelling need to find alternatives for the treatment 
of osteoporosis. Several materials with different properties (in terms of stability, 
functionality, degradability, biocompatibility and antigenicity) have been clinically 
developed. These “intelligent” materials are useful in the field of tissue engineering 
because they have the ability to mimic the natural environments of the cells [7]. 
 
1.3 Bone tissue engineering 
Indeed, tissue engineering (TE) represents a valid alternative for treating and restoring 
bone defects, considering that every year in the United States there are approximately 
900,000 hospitalizations due to bone fractures which require intervention [8]. TE was 
only defined in the mid-1980s. Skalak and Fox firstly defined tissue engineering as “the 
application of principles and methods of engineering and life sciences towards the 
fundamental understanding of structure-function relationships in normal and 
pathological mammalian tissues and the development of biological substitutes to restore, 
maintain or improve tissue function”[9]. The discipline applies the principles of 
engineering and sciences, such as biology and medicine to biological substitutes (Figure 
3), which can be used to restore, maintain or improve bone tissue function [10]. TE seeks 
to maintain and restore the function of human bone tissue by combining cell biology, 
materials science and principles of engineering principles. 
The general principle is based on the development of matrices, which consequently can 
be incorporated into the body. Matrices are generally composed of natural or synthetic 
polymers. Indeed, TE is a promising alternative approach to treat the loss of tissues or 
organs without the limitations of current therapies. Specifically, the current research 
emphasizes biodegradable polymers, combining specific structures with osteogenic 
precursor cells. Several biodegradable materials have been considered for the preparation 
of three-dimensional porous scaffolds for bone tissue engineering [11]. The use of these 
materials is explained by their similarity to extracellular matrix, chemical versatility, 
biological performance and cellular interactions. The scaffolds or three-dimensional (3D) 
constructs provide support to cells to proliferate and maintain their differentiated function 
[12]. Figure 4 shows that TE is composed of different steps: 1) cells need to be extracted 
from the patient or a donor; 2) cells then can grow and expand in in vitro conditions; 3) it 
then becomes possible to implant the cells in a matrix, defined as a scaffold. 4) The 
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scaffold should offer a suitable environment to promote cell growth and differentiation; 
5) scaffold-containing cells can be implanted into the patient by the surgeon [13]. 
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Figure 3. Multidisciplinary tissue-engineering. 
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Figure 4. Steps in the tissue engineering approach. 
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1.3.1 Tissue engineering approach 
In the last decade, as life expectancy continues to increase, the need for new bone 
substitutes in order to promote bone replacement is growing very rapidly. As a result, 
there is a great demand for biomaterials with specific anti-inflammatory, antibacterial and 
regenerative properties [14]. In recent years, considerable attention has been given to 
regenerative medicine and tissue engineering to replace bone tissue. In this context, the 
main challenge in tissue engineering is to develop biomaterial-bases which induce stem 
cell response in terms of osteogenic differentiation. Since the 1990s, numerous materials 
for supporting cell attachment, growth, and differentiation, as well as new stem cell 
sources and bioactive molecules have been identified in order to improve bone tissue 
regeneration following lesions derived from osteoporosis. Research has developed new 
experimental methods for tissue regeneration using the combination of 3 key elements, 
namely, stem cells, bioactive molecules (e.g., growth factors), and scaffolds [15]. 
Scaffolds mimicking extracellular-matrix endow mechanical support, promote biological 
response and regulate bioactive molecule effects [16]. 
 
1.3.2 Cell-material interaction 
The success of a biomaterial in tissue regeneration processes depends on its ability to 
interact with the physiological environment and specifically with cells [17]. The cell-
material interaction process is composed of different stages. The first stage consists of the 
contact between material surface and water molecules forming a water coating layer. This 
step is highly dependent on the material surface properties. The second step is 
characterised by the interaction of all the existing macromolecules in the physiological 
medium, namely sugars, lipids and proteins with the material surface which influences 
material biocompatibility. Surface features, surface energy and the chemical composition 
of the material strongly influence the cell-material interaction process determining the 
nature of the proteins adsorbed to the surface and their orientation and conformation, 
which are crucial parameters. Finally, in a third stage, cells directly interact with material. 
Cell-material interaction takes place through cell adhesion proteins known as integrins 
that interact with particular peptide motifs from the protein adsorbed to the material 
surface. Integrins are cell transmembrane proteins that possess two units of glycoproteins 
(α and β) and three domains (cytoplasmic, transmembrane and extracellular). The 
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extracellular domains of the α and β units possess receptors for the specific recognition of 
cell adhesive peptide motifs that are contained in some adhesive proteins present in the 
ECM [18-20]. 
 
1.4 Mesenchymal stem cells: tools for bone tissue regeneration  
Several research studies have been performed on mesenchymal stem cells (MSCs) 
capable of generating several tissue types including bone tissue. It was widely reported 
that MSCs isolated from bone marrow in combination with scaffolds and growth factors 
are able to regenerate bone tissue both in vivo and in vitro experimental models [21]. At 
present, the main challenge in regenerative medicine is to identify the ideal scaffold to 
enhance MSCs’ residing response in terms of cell growth, spreading, adhesion and 
differentiation. Phenotypically, MSCs express the CD13, CD29, CD44, CD59, CD73, 
CD90, CD105, CD146 and STRO-1 surface antigens, and they do not express CD45 (a 
leukocyte marker), CD34 (the marker for primitive hematopoietic progenitor and 
endothelial cells), CD14 and CD11 (markers for  monocytes and macrophages), CD79 
and CD19 (B cell markers), or HLA class II. Most current tissue engineering approaches 
suggested the use of MSCs taken from sites that are even more accessible and rich in 
stem cells because the ability of stem cells to renew themselves indefinitely and 
differentiate into multiple types of more specialized cell phenotypes. However, these 
regenerative mechanisms decrease with age and cells lose the ability to repair damaged 
tissues [22]. Tissue engineering introduced the combination of biomaterials, growth 
factors and stem cells to overcome a lack of “self-renewal” in damaged tissue [23]. In this 
context, as previously reported, scaffold properties are crucial to enhancing MSCs’ 
biological response. To satisfy the aims of regenerative medicine MSCs should 
demonstrate the following features: they should be in abundant in number, able to 
differentiate in multiple cell lineages, and able to be isolated using minimally invasive 
procedures, produced according to GMP (Good Manufacture Practice) and transplanted 
safely [24-26]. Commonly three main types of stem cells are used for tissue repair: i) 
embryonic stem cells derived from embryos (ES); ii) adult stem cells that are derived 
from adult tissue; and iii) induced Pluripotent Stem (iPS) cells that have been produced 
artificially via genetic manipulation of the somatic cells [27]. ES and iPS cells are 
pluripotent stem cells because of their ability to differentiate into all types of cells from 
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all three germinal layers. On the other hand, adult stem cells are multipotent because they 
are only able to differentiate into a restricted number of cell types. Initially, it was widely 
reported that each type of tissue possesses a specific area called the “stem cell niche” 
containing adult stem cells. MSCs were isolated from bone marrow for the first time by 
Friedenstein et al. in 1974 [28]. To date, MSCs can be isolated from different tissues 
including peripheral blood, umbilical cord blood, and amniotic membrane, adult 
connective, adipose and dental tissues [29]. Mesenchymal stem cells (MSCs) represent a 
great source of specific biomaterials that can manipulate the fate of stem cells and lead to 
high quality tissue regeneration for bone defect therapy [30]. In fact, besides controlling 
the fate of stem cells, the biomaterials play a pivotal role in regulating MSCs’ many 
physiological functions including survival and host immune system control [31]. The 
immune response plays a key role in several bone tissue degenerative and regenerative 
processes. In fact, it was widely reported that pro-inflammatory mediators such as TNF-α 
(tumour necrosis factor alpha) and IFN-γ (Interferon gamma) induced down-regulation of 
osteogenesis thus inhibiting MSC-mediated bone regeneration [32]. Thus, by using 
biomaterials functionalised with specific signals it is possible to protect MSCs from the 
host immune cell/cytokine insult and regulate the crosstalk between immune cells and 
MSCs. These new tissue-engineering approaches make stem cell-based therapies a very 
promising long-term alternative in the treatment of bone defects due to the possibility of 
regenerating bone tissue and keeping the structural integrity and physiological functions 
of bone. Furthermore, by using new biomaterials it is possible to control innervation and 
vascularisation in stem cell niche homeostasis, thus promoting stem cell response in 
terms of angiogenesis, another important stage in new bone tissue formation [33]. In 
order to generate the formation of new bone tissue MSCs are isolated, expanded in 
culture and finally seeded within or onto a natural or synthetic scaffold that can reproduce 
the shape of the newly forming tissue and then the newly formed “organoid” can be 
transplanted into the patient. In this context another approach consists of the direct 
implantation of a cellular scaffold into the bone defect so the body cells can populate the 
scaffold to form the new tissue in situ. 
 
1.5 Human umbilical vein endothelial cells (HUVECs) 
Endothelial cells (EC) are of particular interest in regenerative medicine [34]. Endothelial 
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cell structure and function alterations may significantly contribute to diseases of blood 
vessel such as thrombosis, atherosclerosis, and vasculitis. The construction of stable 
blood vessels is an important challenge in the field of tissue engineering.  It is possible to 
introduce genes for bone tissue regeneration in devices that can enhance the survival 
and/or proliferation of vascular cells and endothelial cells (EC) in order to extend the 
lifespan of the engineered vessels [35]. EC have an important role in physiological 
hemostasis, blood vessel permeability [36] and blood vessel response to physiological 
and pathological stimuli [37]. Therefore, EC are currently used as in vitro model systems 
to investigate various physiological and pathological processes, especially in 
angiogenesis research. In recent years, many researchers have established and 
characterised EC lines. It is well known that endothelial cells are involved in many 
biological events. Several studies have suggested that these cells are very sensitive to 
growth factors and biological agents and they can repeatedly be extended. In fact, 
Fibroblast Growth Factor (FGF) or thrombin stimulates these cells, inducing a 
proliferative response [38]. Human vascular endothelial cells also respond to Epidermal 
Growth Factor (EGF), but their rate of proliferation is slower than when maintained with 
FGF and thrombin [39]. Thus, the set of factors controlling vascular endothelial cells 
proliferation may depend on the vascular endothelial cells’ origins. Generally, EC include 
cell types of various origin; primary and immortalised bovine aortic endothelial cells 
(BAEC), primary human umbilical vein endothelial cells (HUVECs), primary human 
microvascular endothelial cells (HMECs), primary human dermal microvascular 
endothelial cells (HDMECs) and immortalised microvascular endothelial cells (HMEC-
1). The availability of these cells has played a crucial role in the development of the field 
of vascular biology [40]. Particularly, human umbilical vein endothelial cells 
(HUVECs) have played a major role as a model system in order to study endothelial 
cell function regulation. It is no simple matter to decide which cell line is better to use 
for the final aim of research. In this context, HUVECs have a crucial role in the 
response of the blood vessel wall to stretch, shear forces, and the development of 
atherosclerotic plaques and angiogenesis. In fact, HUVECs are popular and easy to 
isolate in laboratories [41]. The human umbilical cord is one of the most important 
sources of vascular endothelial progenitor cells. HUVECs are isolated from freshly 
obtained human umbilical cords through the collagenase digestion of the interior of the 
umbilical vein. A sterile technique is used in all manipulations. After birth, the umbilical 
cord is severed from the placenta and placed in a sterile container filled with cord buffer 
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(0.14 M NaCl, 0.004 M KCI, 0.001 M phosphate buffer, pH 7.4, and 0.011 M glucose). 
Then, perfusion of the human umbilical cord vein with collagenase permits the attainment 
of a pure preparation of the single layer of endothelial cells that line this vessel [42]. The 
cells at initial passages, which grow in the presence of heparin and pituitary extract, 
maintain nearly the same features as native vascular endothelial cells. Characteristics 
include the expression of endothelial cell specific markers such as von Willebrand factor 
and an endothelial cell specific adhesion molecule, CD31, expression of receptors for 
growth factors, cytokines, vasoactive ligands, and specific signalling pathways for 
vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), transforming 
growth factor-β, tumour necrosis factor (TNF-α) and angiotensin II [43]. Hence, under in 
vitro culture conditions, HUVECs show a typical “cobblestone” morphology and 
spontaneously form tubules. Furthermore, several studies demonstrate that these cells can 
be induced to form tubules in cell culture if deprived of endothelial cell growth factor 
(ECGF) for 4 to 6 weeks [44]. Additionally, scanning electron microscopy analyses show 
that cultured human endothelial cells grow as monolayers of closely opposed, polygonal 
large cells. Under transmission electron microscopy, the cells seem to contain 
cytoplasmic inclusions (Weibel-Palade bodies) characteristic of in situ endothelial cells. 
These inclusions were also found in endothelial cells lining umbilical veins but were not 
seen in smooth muscle cells or fibroblasts in culture or in situ. [45]. Indeed, HUVECs 
provide a critical in vitro model for major breakthroughs in molecular medicine including 
seminal insights into cellular and molecular events in the pathophysiology of 
atherosclerosis and plaque formation, and mechanisms for angiogenesis control or 
neovascularisation in response to hypoxia and inflammation in tumours, ischemic tissue, 
and in embryogenesis [46]. Moreover, monolayers of HUVECs have been studied for 
endothelial cell layer/leukocyte and macrophage interaction in vascular tissues. This was 
useful in the discovery of adhesion molecules, chemokines and kinases, which mediate 
the interaction of inflammatory cells with the endothelial surface and their migration into 
the media. HUVEC monolayers are generated on deformable surfaces or in chambers, 
which allow for the study of the effects of shear stress and pulsatile flow on cell 
signalling in order to reproduce the effects of blood flow on endothelial cell function in 
vivo. These monolayers have been used to identify transcription factors such as KLF2, 
which regulate the expression of adhesion molecules such as vascular cell adhesion 
molecule-1 and endothelial adhesion molecule E-selectin in response to stress and 
proinflammatory cytokines such as TNF-α which mediate changes in cell adhesion and 
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migration. This plays a role in early changes in atherosclerosis. Cultured endothelial cells 
contain a large amount of smooth muscle actomyosin and ABH antigens appropriate to 
the tissue donor's blood type; these antigens are not detectable on cultured smooth muscle 
cells or fibroblasts. This evidence demonstrates that it is possible to culture 
morphologically and immunologically identifiable human endothelial cells for a period of 
up to 5 months. HUVECs are endothelial cells of human origin with characteristics 
similar to the parent endothelial cell. They exhibit positive acetylated low-density 
lipoprotein (AcLDL) uptake, express eNOS, CD31 and V-cadherin, and spontaneously 
form capillary-like structures when grown on Matrigel. HUVECs also maintain 
endothelial cell characteristics at the mitogenesis, kinase activation and vasodilator 
production level. Moreover, they express key proteins necessary for vasodilator 
production, including epithelial nitric oxide synthase (eNOS), HSP 90, cav-1 and -2, 
cPLA2, and COX-1 and -2. In HUVECs, receptors for angiotensin II (AII), bradykinin, 
ATP and growth factors have been detected. Thus HUVECs appear to be functionally 
very similar to primary cell line and they will prove a valuable tool for future studies in 
therapeutic sciences. Moreover, the data strongly suggests that HUVECs are a pure 
population of endothelial cells and the production of vasodilators such as nitric oxide 
(NO) and prostacyclin (PGI2) by endothelial cells is an essential factor when it comes to 
maintaining the balance between vasodilation and vasoconstriction [46]. More 
substantially, HUVECs represent a valid tool for studying the angiogenesis process in 
order to assess the potential angiogenic effect of biocomposites in tissue engineering 
applications. Consequently, the research pays great attention to HUVECs use in the study 
of angiogenesis and vasculogenesis processes. 
 
1.6 Porous scaffold for tissue engineering 
A wide variety of polymer scaffolds, both synthetic (e.g., poly [lactic] acid) and natural 
(e.g., collagen), ranging from macroporous structures obtained through salt 
leaching/solvent casting and gas foaming, to nanofibrous scaffolds processed via 
electrospinning, self-assembly, and phase-separation have been realized for regeneration 
of bone tissue [47]. In order to mimic bone mass structure, approaches in scaffold design 
must be able to create 3D hierarchical porous structures for the desired mechanical 
function and mass transport (that is, permeability and diffusion) properties. Porous 
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hierarchical structures present pores of different size at scales from the nanometre to 
millimetre level that influence mechanical functions, nutrients transport and cell 
migration. Biodegradable scaffolds with these features provide temporary mechanical 
support to bone tissue regeneration. In fact, they must degrade into biocompatible 
products, ideally on a time scale comparable to that of new tissue development. Many 
scaffolds are typically fabricated with biocompatible polymers, proteins, peptides, and 
inorganic materials. Today, four types of material have been studied experimentally and 
clinically as scaffold material: (A) synthetic organic materials; (B) synthetic inorganic 
materials: hydroxyapatite, tricalcium-phosphate; (C) organic materials of natural origin: 
collagen, hyaluronic acid; (D) inorganic material of natural origin: coralline 
hydroxyapatite [48]. The ideal scaffold should be highly biocompatible so as not to elicit 
immunological or clinically detectable primary or secondary foreign body reactions. 
However, biocompatibility or tissue tolerance is not enough. Henche and Ethridge 
expressed a general theory of biomaterials in 1982 [49]. 
An ideal implant material should perform as if it were equivalent to the host tissue 
 The tissue at the interface should be equivalent to the normal host tissue 
 
 The response of the material to physical stimuli should be like that of the 
tissue replaced 
Moreover, the 3D scaffold surface can be functionalised to promote cell adhesion through 
specific cell–matrix interactions. In fact, the formation of complex tissues from single 
cells and tissue maintenance needs large amounts of information, which must be 
transported from cell to cell, and from cells to ECM. Scaffold activity is also conferred by 
chemical composition, which determines the identity of ligands; the specific surface of 
the porous network; the orientation of pore channels, which determines the spatial 
configuration of ligands; and degradation rate of the scaffolds which depends on the 
chemical composition as well as the cross-link density of the macromolecular network 
and determines the duration of the active surface. In bone tissue engineering, an 
understanding of the bone-forming behaviour of cells must be combined with progress in 
material science, to achieve guided bone regeneration. Starting from the 1950s, in bone 
regenerative applications there was a predominant use of metal implants and associated 
devices with a good effectiveness on local tissues. In the 1970s and 1980s, polymers and 
synthetic materials able to enhance cell biological responses began replacing metal 
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implants. Recently, many efforts have been made to design both natural and degradable 
scaffolds in three dimensions, that are structurally more acceptable and more able to 
completely regenerate tissue [50]. Recent findings have shown that alginate and/or 
chitosan (natural polymers) are also useful in achieving injectable biomaterial-based 
scaffolds for clinical applications aimed at regenerating teeth including dentinal-wall-
thickening, root maturation, and, in some cases, the formation of reparative cementum-
like tissue [51]. In the context of porous scaffolds, a natural polymer, chitosan has 
received much attention in the regenerative field because of its positive properties. Many 
studies on chitosan-based scaffold preparation and their in vitro biological response were 
performed in order to promote bone regeneration [52]. It is well-known that chitosan is 
biocompatible, non-toxic and mechanically stable. It is also suitable for interactions with 
soft tissues due to its porous structure and possesses chemical groups, which can be easily 
functionalized or bio-activated chemically. Furthermore, chitosan has a high affinity for 
in vivo macromolecules and seems to be a good potential material for other tissues such 
as skin, adipose, cornea, liver, nerve and blood vessel. 
 
1.6.1 Biomimetic treatment of scaffold for bone regeneration 
Many bioactivation strategies may be applied in order to obtain scaffold with 
osteoinductive properties for bone regeneration applications. In this thesis, the scaffold 
surface was bioactivated with dual osteogenic signals: organic and inorganic. Organic 
approaches include the osteogenic peptides and proteins immobilization on the scaffold 
surface. In fact, short sequences mimicking proteins of Bone Morphogenic Protein 
(BMP) such as BMP-2 can be synthetized and immobilised on scaffold in order to 
improve the osteoinductive properties of biomaterials. On the other hand, inorganic 
approaches consist of coating with apatite using a supersaturated SBF solution (5xSBF). 
The solution induces hydroxyapatite nuclei formation, according to the method described 
by Kokubo and co-workers [53]. Specifically, we used an accelerated treatment, which 
combines the preliminary use of a supersaturated SBF solution (5xSBF1) to stimulate the 
formation of nuclei, while a fresh chemically modified solution (5xSBF2) is used, in order 
to promote the growing of apatite nuclei, once nuclei are formed. Meanwhile, 5xSBF1 
was prepared by sequentially dissolving CaCl2, MgCl2·6H2O, NaHCO3 and 
K2HPO4·3H2O in distilled water. Solution pH was lowered to 6 by adding hydrochloric 
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acid HCl (1M) to increase the solubility. Na2SO4, KCl were added until the previous 
solution become clear. The final pH was adjusted with 1M NaOH to reach a final pH 
equal to 6.5 (5xSBF1). Therefore, Mg
2+
 and HCO3
-
 free 5xSBF was prepared by 
subsequently adding CaCl2, K2HPO4·3H2O to distilled water up to obtain a fresh solution 
(5xSBF2). In this case, the solution pH was lowered to 6.0 with hydrochloric acid to 
increase the solubility. Both solutions were buffered at pH 6.5 and 6 respectively, by 
using Tris hydroxymethyl aminomethane-chloric acid (Trizma-HCl). Table 1 reported the 
ionic concentration of blood plasma, SBF, 5xSBF1 and 5xSBF2. All solutions were 
prepared freshly before use.The biomimetic treatment consists of two steps in a pH-
controlled environment: during the first step, samples of the pre-ordered size were soaked 
into 5xSBF1 at pH=6.5 where the 5xSBF solution volumes have been calculated in 
respect to the total scaffold material surface by using an exposed surface to SBF volume 
ratio equal to 10 mm
2
/ml, as reported in the literature [54]. 
Solution temperature was fixed at 37 °C during the treatment. After the sequential 
immersion in 5xSBF1 (4 days) and in 5xSBF2 (3 days), all scaffolds were gently rinsed in 
distilled water to remove excess ions and, then dried overnight under a laminar flow 
hood. 
 
Table1: The ionic concentration of human blood plasma, SBF, 5xSBF1 and 5xSBF 
 
 
 
1.7 Injectable calcium phosphate materials 
Minimally invasive surgery (MIS) in the treatment of routine and complex orthopaedic 
conditions presents a useful approach for the patient [55]. The traditional surgical 
approach typically involves an incision of five inches or larger. These larger incisions can 
cause many risks, which may include significant blood loss, tissue or nerve damage, and 
a greater risk for infection. Due to these large incisions, surgery may be delayed for 
weeks. Such delays may have undesirable consequences for patients such as  prolonged 
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pain, increased leave from work, and even further complications. The MIS approach, 
which typically involves pin size incisions resulting in less blood loss and tissue damage, 
reduces risk for post-operative infection. When compared to the traditional approach, 
MIS shows certain benefits, among them a much faster healing and recovery period. As a 
result of the increasing popularity of MIS, a interest in the use and development of 
injectable biodegradable materials for regeneration of bone has grown, too. Tissue 
engineering strategies are based on the use of very promising injectable materials for use 
in bone regeneration. These injectable biomaterials permit the incorporation and the 
release of therapeutic agents, such as antimicrobial and anti-inflammatory drugs as well 
as bioactive molecules that can trigger stem cell differentiation to aid in the regeneration 
of bone structure. To this end, after calcium phosphate-based ceramics such as 
hydroxyapatite (HA), beta-tricalcium phosphate (β-TCP) and the HA/β-TCP association 
that replaced bone autografts thanks to a chemical composition closely related to that of 
bone mineral, a ready-to-use injectable bone substitute (IBS) has been developed. The 
effectiveness of these IBS depends on the fact that the newly formed bone contains the 
same Ca and P values as in basal bone and makes it possible for IBS to satisfy immediate 
implantation requirements. For this reason, injectable composite biomaterials are of 
primary importance for clinical applications such as socket filling and pre-implant 
reconstruction. The sol-gel method has recently attracted much interest as a new 
technique for IBS synthesis because it permits improvement in the chemical homogeneity 
of the resulting HA compared to conventional methods such as solid-state reactions, wet 
precipitation, and hydrothermal synthesis. In particular, the Sol-gel method is useful for 
the synthesis of HA-based injectable materials to possibly obtain nanoparticles that are 
able to rapidly improve stability at the artificial/natural bone interface [56]. 
Hydroxyapatite is the most studied biomaterial for medical applications due to both its 
high biocompatibility and for being the main constituent of the mineral part of bone [57]. 
Hydroxyapatite, HA [Ca10(PO4)6(OH)2] possesses a chemical structure similar to the 
mineral components of bones. In fact, its structure looks like crystalline bioapatite 
mineral composed of 45% by volume, and 65% by weight of the mineral fraction of 
human bone. However, the extracellular matrix of bone has been described as a 
composite material composed of collagen type I fibrils mineralized with hydroxyapatite 
nanocrystals. Approximately 70% of bone by weight is composed of calcium salts, with 
hydroxyapatite (Ca10(PO4)6(OH)2 as the primary mineral constituent. In other words, 
bone mineral is not purely hydroxyapatite, and the presence of ion impurities has actually 
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led to the consensus that a more accurate term for the inorganic component is carbonate 
hydroxyapatite with the formula (Ca,Mg,Na)10(PO4HPO4CO3)6(OH)2. Devoid of an 
organic component, calcium salts such as hydroxyapatite are biocompatible, non-
immunogenic components of bone and are considered osteoconductive. Consequently, 
there has been much interest in designing synthetic osteoconductive grafting materials 
based on these naturally occurring calcium salts. HA is widely used to repair, fill, extend 
and reconstruct damaged bone tissue. This crystalline molecule was used as a coating for 
metallic implants in order to improve the osteoconductive and osteointegrative properties 
of prostheses. It can be synthesized via reactions in solid state, coprecipitation, 
hydrothermal methods, or sol-gel process, among others. Precipitation in aqueous 
solutions is the experimental procedure most employed because HA is insoluble in water. 
The molar ratio of calcium to phosphorus Ca/P varies from 1.2 to almost 2 in HA. The 
stoichiometric molar ratio of HA is 1.67; however, this is not the value observed in the 
organism because small amounts of other materials such as carbon, nitrogen, iron and 
other elements are incorporated. Thus, the general chemical formula is 
Ca10x(HPO4)x(PO4)6x(OH)2. Young and Posner determined the crystal structure of HA. 
Hydroxyapatite can be produced with either a dense or a macroporous morphology, and 
is typically sintered at temperatures above 1000 °C in granular or block forms. The high 
heat of sintering produces a material that cannot be reshaped to fit into a bone defect (i.e. 
a block form) and is non-resorbable. Beta-tri-calcium phosphate (β-TCP) has the formula 
Ca3(PO4)2 and like hydroxyapatite is a brittle material with low fracture resistance. A 
variety of CaP compounds have been used for the solid phase such as dicalcium 
phosphate, dicalcium phosphate dihydrate, calcium-deficient hydroxyapatite, and 
amorphous calcium phosphate. These cements are injectable and mouldable for variable 
periods before hardening. They are also described as resorbable, though clinical 
experience has demonstrated the retention of the material over extended periods. At the 
beginning of the 1970s, it was shown that HA displayed two crystal systems, hexagonal 
and monoclinic. HA contained in teeth and bones and mineral HA present a hexagonal 
structure; unlike dental enamel HA has a monoclinical structure. HA obtained in the lab 
presents a structure which depends on the of method synthesis. For example, IBS 
biomaterials based on HA precursors and obtained by using the sol-gel method can be 
enriched with therapeutic molecules and compounds. In the last decade, greater attention 
has been paid to the study of devices for bone regeneration, which possess a dual 
function: to stimulate the newly forming bone tissue and prevent bacterial infections. 
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Microbial infection prevention is important because the bone implant failure often occurs 
due to implant-associated bacterial infections and inflammation, which inhibit adequate 
osseointegration [50]. As result, these infections can cause systemic pathologies, thus 
increasing the costs of hospitalization for patients. Several approaches were attempted in 
order to obtain antibacterial effects by using biomaterials functionalized with 
antimicrobial agents. Over the last few years, among these new approaches a wide class 
of ionic liquids (ILs) have been counted as antimicrobial agents. Ionic liquids are large 
organic cations, such as imidazolium or pyridinium, with alkyl chain substituents that 
alter the hydrophobicity of the molecule. Recently, several studies showed the possibility 
to combine ILs with such biomaterials or bone precursors in order to obtain 
osteoinductive and antibacterial effects. 
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2. Thesis aim 
Osteoporosis is a musculoskeletal disorder with a high social impact. In fact, fractures 
derived from the inflammatory bone loss associated with osteoporosis cause long-term 
disability in the elderly and significant economic burdens. Current conventional therapy 
for osteoporosis consists of systemic administration of bisphosphonates and anti-
inflammatory drugs. However, these drugs in long-term treatment induce complications 
and serious side effects such as gastrointestinal (GI) diseases, fever and articular pain. 
The main aim of this thesis is to propose new alternative therapies for osteoporosis in the 
field of tissue engineering, in order to overcome the drawbacks related to systemic 
therapy for osteoporosis care. In particular, the present study suggests the possibility of 
preventing and treating locally osteoporotic bone fractures by using biomimetic 3D 
scaffolds (chitosan-based scaffolds) with osteoinductive and angiogenic properties. 
Moreover, in the current study we have analysed the effect of injectable CaP based 
biomaterials functionalised with ionic liquids (ILs), useful for the regeneration of some 
osteoporotic lesions. The choice of ILs is due to their well-known antibacterial and 
antifungal properties in order to combine the bone regenerative effects of CaP with the 
opportunity to prevent and treat the bone infections associated with osteoporotic fractures 
with ILs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26 
 
References  
[1] G Anderson “Bone matrix composition and methods for making and using same”. US 
Patent, 2002. US6340477 B1. 
[2] P Podsiadlo, AK Kaushik, EM Arruda, AM Waas. “Ultrastrong and stiff layered 
polymer nanocomposites”. Science 2007;318:80-83. 
[3] Kyle M. Schweser and Brett D. Crist
 “Osteoporosis: a discussion on the past 5 years” 
Curr Rev Musculoskelet Med. 2017;10:265–274. 
[4] TD Rachner, S Khosla, LC Hofbauer “Osteoporosis: now and the future”. Lancet 
2011;377:1276-1287. 
[5] R Nikander, H Sievänen, A Heinonen "Targeted exercise against osteoporosis: a 
systematic review and meta-analysis for optimizing bone strength throughout life”. BMC 
Medicine 2010;8:47. 
[6] P Kothawala, E Badamgarav, S Ryu, RM Miller “Systematic review and meta-
analysis of real-world adherence to drug therapy for osteoporosis”. Mayo Clinic 
2007;82:1493-1501. 
[7] M Caldorera-Moore, NA Peppas "Micro-and nanotechnologies for intelligent and 
responsive biomaterial-based medical systems”. Advanced drug delivery reviews 
2009;61:1391-1401. 
[8] G Chen, T Ushida, T Tateishi, “Scaffold design for tissue engineering”. 
Macromolecular Bioscience 2002;2:67–77. 
[9] FJ O'brien, “Biomaterials & scaffolds for tissue engineering”. Materials today 
2011;14:88-95. 
[10] B Dhandayuthapani, Y Yoshida, T Maekawa. “Polymeric scaffolds in tissue 
engineering application: a review”. International Journal of Polymer Science 
2011;2011:19. 
 27 
 
[11] K Rezwan, QZ Chen, JJ Blaker, AR Boccaccini. “Biodegradable and bioactive 
porous polymer/inorganic composite scaffolds for bone tissue engineering”. Biomaterials 
2006;27:3413-3431. 
[12] F Pampaloni, EG Reynaud, Stelzer, HK Ernest. “The third dimension bridges the 
gap between cell culture and live tissue”. Molecular Cell Biology 2007;8:839–845. 
[13] D Marolt, G Vunjak-Novakovic “Bone tissue engineering with human stem cells”, 
Stem cell 2010;1:10. 
[14] MG Raucci, M Alvarez-Perez, D Giugliano, S Zeppetelli, L Ambrosio. “Properties 
of carbon nanotube-dispersed Sr-hydroxyapatite injectable material for bone defects”. 
Regenerative biomaterials 2016;3:13-23. 
[15] MT Albuquerque, MC Valera, M Nakashima, JE Nör, MC Bottino. “Tissue-
engineering based strategies for regenerative endodontics”. J Dent Res 2014;93. 
[16] NG Rim, CS Shin, H Shin "Current approaches to electrospun nanofibers for tissue 
engineering”. Biomedical materials 2013;8-1. 
[17] J Sun, H Tan “Alginate-based biomaterials for regenerative medicine applications”.  
Materials 2013;6:1285-1309. 
[18] J A Plannel, M Navarro “Developing targeted biocomposites in tissue engineering 
and regenerative medicine”. In: Ambrosio L, Biomedical composites 2010:569–587. 
[19] C D Mc Farland, S Mayer, C Scotchford, B A Dalton, J C Stelle, S Downes 
“Attachment of cultured human bone cells to new polymers”. J Biomed Mater Res 
1999;44: 1-11. 
[20] M C Siebers, P J Ter Brugge, X F Walboomers, J A Jensen “Integrins as linker 
proteins between osteoblasts and bone replacing materials”. A critical review. 
Biomaterials 2005;26:137-146. 
[21] J Van den Dolder, E Farber, PH Spauwen, JA Jansen “Bone tissue reconstruction 
using titanium fiber mesh combined with rat bone marrow stromal cells”. Biomaterials 
2003;24:1745-1750. 
 28 
 
[22] A Moshaverinia, C Chen, X Xu, S Ansari, HH Zadeh, SR Schricker, ML Paine, J 
Moradian-Oldak, A Khademhosseini, ML Snead, S Shi “Regulation of the Stem Cell-
Host Immune System Interplay Using Hydrogel Coencapsulation System with an Anti-
Inflammatory Drug”. Adv Funct Mater 2015;25:2296-2307. 
[23] S Sundelacruz, DL Kaplan. “Stem cell- and scaffold-based tissue engineering 
approaches to osteochondral regenerative medicine”. Seminars in cell & developmental 
biology 2009;20:646-655. 
[24] JM Gimble, AJ Katz, BA Bunnell. “Adipose-derived stem cells for regenerative 
medicine”. Circulation research 2007;100:1249-60. 
[25] Babak Pourmollaabbassi , Batool Hashemibeni ,  Ebrahim Esfandiari “Review 
Paper: Adipose Tissue, Adipocyte Differentiation, and Variety of Stem Cells in Tissue 
Engineering and Regeneration” ASJ. 2016;13:85-98. 
[26] SJ Bidarra, CC Barrias, PL Granja “Injectable alginate hydrogels for cell delivery in 
tissue engineering”. Acta biomaterialia 2014;10:1487-1770. 
[27] J Yu, MA Vodyanik, K Smuga-Otto, J Antosiewicz-Bourget, JL Frane, S Tian, J 
Nie, GA Jonsdottir, V Ruotti, R Stewart, II Slukvin, JA Thomson. “Induced pluripotent 
stem cell lines derived from human somatic cells”. Science 2007;318:1917-20. 
 [28] R Izadpanah, C Trygg, B Patel, C Kriedt, J Dufour, JM Gimble, BA Bunnell. 
“Biologic properties of mesenchymal stem cells derived from bone marrow and adipose 
tissue”. J Cell Biochem 2006;99:1285-97. 
[29] T Nagamura-Inoue, H He “Umbilical cord-derived mesenchymal stem cells: Their 
advantages and potential clinical utility”. World J Stem Cells 2014;6:195–202. 
[30] L Xiao, M Nasu “From regenerative dentistry to regenerative medicine: progress, 
challenges, and potential applications of oral stem cells”. Stem Cells Cloning 
2014;7:89–99. 
[31] R Sridharan, AR Cameron, DJ Kelly, CJ Kearney “Biomaterial based modulation of 
macrophage polarization: a review and suggested design principles”. Materials Today 
2015;18:313-25. 
 29 
 
[32] TK Kovach, AS Dighe, PI Lobo, Q Cui “Interactions between MSCs and immune 
cells: implications for bone healing”. Journal of Immunology 2015;752510.  
[33] U Kini, BN Nandeesh “Physiology of bone formation, remodeling, and metabolism”. 
Radionuclide and hybrid bone imaging 2012:29-57. 
[34] KR Chien  “Regenerative medicine and human models of human disease”. Nature 
2008;453:302-5.  
[35] S Baiguera, D Ribatti “Endothelialization approaches for viable engineered tissues”. 
Angiogenesis 2013;16:1-14.  
[36] D Mehta, AB Malik  “Signaling mechanisms regulating endothelial permeability”. 
Physiological reviews 2006:86:279-367. 
[37] GL Semenza “Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms 
of blood vessel formation and remodeling”. Journal of Cellular Biochemistry 
2007;102:840-847. 
[38] S Barrientos, O Stojadinovic, MS Golinko “Growth factors and cytokines in wound 
healing”. Wound Repair 2008; 16: 585-601. 
[39] ED Miller, GW Fisher, LE Weiss, LM Walker “Dose-dependent cell growth 
in response to concentration modulated patterns of FGF-2 printed on fibrin”. 
Biomaterials 2006;27:2213-21. 
[40] I Geudens, H Gerhardt  “Coordinating cell behaviour during blood vessel 
formation”. Development 2011;138:4569-4583. 
[41] N Jiménez, VJD Krouwer, JA Post  “A new, rapid and reproducible method to 
obtain high quality endothelium in vitro”. Cytotechnology 2013;65:1-14. 
[42] E Cairrao, AJ Santos-Silva, E Alvarez, I Correia "Isolation and culture of human 
umbilical artery smooth muscle cells expressing functional calcium channels”. In Vitro 
Cell Dev Biol Anim. 2009;45:175-184. 
[43] AV Sima, CS Stancu, M Simionescu  “Vascular endothelium in atherosclerosis”. 
Cell and tissue research 2009;335:191. 
 30 
 
[44] V Krasnoperov, N Kertesz, R Reddy, P Gill “Polypeptide compounds for inhibiting 
angiogenesis and tumor growth”. US Patent, 2017;US9533026 B2. 
[45] J Zhang, Q Lian, G Zhu, F Zhou, L Sui, C Tan “A human iPSC model of Hutchinson 
Gilford Progeria reveals vascular smooth muscle and mesenchymal 
stem cell defects”.  Cell stem cell 2011;8:31-45. 
[46] HJ Park, Y Zhang, SP Georgescu, KL Johnson, D Kong, JB Galper. “Human 
umbilical vein endothelial cells and human dermal microvascular endothelial cells offer 
new insights into the relationship between lipid metabolism and angiogenesis”. Stem Cell 
Rev 2006. Review;2:93-101. 
[47] E Carletti, A Motta, C Migliaresi “Scaffolds for tissue engineering and 3D cell 
culture”. 3D Cell Culture 2011;17-39. 
[48] CE Tanase, A Sartoris, MI Popa, L Verestiuc. “In vitro evaluation of biomimetic 
chitosan–calcium phosphate scaffolds with potential application in bone tissue 
engineering”. Biomedical Materials 2013;8:2. 
[49] J Park, RS Lakes “Biomaterials: an introduction”. Springer Science & Business 
Media 2007;562. 
[50] C Liu, Z Xia, JT Czernuszka “Design and development of three dimensional 
scaffolds for tissue engineering”. Chemical Engineering Research and Design 
2007;85:1051-1064. 
[51] I Fasolino, MG Raucci, L Ambrosio “MSCs and Innovative Biomaterials in 
Dentistry, MSCs and Innovative Biomaterials in Dentistry 2017;43-61. 
[52] RAA Muzzarelli “Chitosan composites with inorganics, morphogenetic proteins and 
stem cells, for bone regeneration”. Carbohydrate Polymers 2011; 83: 1433-45. 
[53] MG Raucci, V Guarino, L Ambrosio “Biomimetic strategies for bone repair and 
regeneration”. Journal of Functional Biomaterials 2012:688-705. 
[54] MG Raucci, D Giugliano, MA Alvarez-Perez “Effects on growth and osteogenic 
differentiation of mesenchymal stem cells by the strontium-added sol–gel hydroxyapatite 
gel materials”. Journal of Materials Science: Materials in Medicine, 2015:26-90. 
 31 
 
[55] GR Scuderi, AJ Tria “Minimally invasive surgery in orthopedics”. Springer Science 
& Business Media 2009;694. 
[56] S Veerachamy, T Yarlagadda “Bacterial adherence and biofilm formation on 
medical implants: a review”. Sage Journal 2014:228. 
[57] MI Sabir, X Xu, L Li “A review on biodegradable polymeric materials for bone 
tissue engineering applications”. Journal of Materials Science, 2009;44:5713-24. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 32 
 
CHAPTER II 
Organic and inorganic bioactive signals for the preparation of 
biomimetic chitosan-based scaffolds for bone tissue regeneration 
 
 Introduction 1.
Living tissue and organ functions are often compromised or removed as a result of 
tumours, trauma or accidents. Therefore, there is a need for the development of devices 
able to support and replace the function of living tissues. The use of biomaterials dates 
back to ancient civilizations. Indeed, some Egyptian mummies have artificial eyes, ears, 
teeth and noses. The tissue engineering approach is based on the development of three-
dimensional scaffolds, which act as temporary substitutes for the removed tissue and 
promote cell proliferation and differentiation [1]. Tissue engineering is an emerging field 
of science that was first defined in 1987 by the National Science Foundation as “an 
interdisciplinary field that applies the principles of engineering and the life sciences 
towards the development of biological substitutes that restore, maintain or improve tissue 
function”.  At present, the loss or failure of a tissue or an organ is one of the most 
frequent and expensive problems in the human health care system. Therefore, the gold 
standard in regenerative medicine is the development of new strategies to regenerate 
human tissue or to reconstruct entire organs using tissue-engineering approaches. Bone 
tissue engineering seeks to maintain and restore human bone tissue function by using cell 
biology combined with materials sciences and engineering principles. Therefore, the 
three main elements for TE are harvested cells, recombinant signalling molecules, and 3D 
matrices. Cells and signalling molecules such as growth factors can be incorporated into 
highly porous biodegradable scaffolds, cultured in vitro, and then the scaffold can be 
implanted into bone defects to induce and stimulate new bone growth. The substratum 
obtained allows cells to attach, proliferate, and differentiate to osteoblast phenotypes in 
order to favour bone health according to the scaffold degradation rate (Figure 1) [2]. 
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Figure 1. Bioactive biomaterials functions in terms of biological response. 
 
 
 
 
 
 
 
 
 34 
 
The scaffold must possess certain requirements to be used successfully in bone tissue 
regeneration. Indeed, it must be biocompatible, must have a suitable interconnected 
microstructure and an optimal porosity to promote cell proliferation and migration. 
Moreover, it needs to support the vascularisation of the newly forming tissue. Indeed, the 
scaffold must  guarantee a porosity of 90% and pore diameter of at least 100 µm. It also 
must possess good mechanical properties to stimulate new tissue growth in accordance 
with its degradation behaviour. In addition to the above, the scaffold must be able to 
promote cell adhesion and retain the metabolic functions of the attached cells. 
Mechanical properties depend on the nature of the biomaterials but also on the 
preparation and fabrication processes, which influence the biological response. The ideal 
scaffold for bone TE should be characterised by a good porosity to organise tissue 
regeneration and guide new tissue in-growth. Also of utmost importance is, creating a 
suitable microarray environment to promote osteoblast proliferation and the osteogenesis 
process. It is well known that the natural bone is a complex inorganic-organic 
nanocomposite material, in which hydroxyapatite (Ca10 (PO4)6 (OH) 2) nanocrystal and 
collagen fibrils are well organized in a hierarchical architecture [3].  Polymers can serve 
as a matrix to support cell growth and they can be easily modified and altered by 
changing the constituents of monomers in different ratio, controlling polymerisation 
conditions or introducing various bioactive functional groups. Polymers including poly 
(glycolic acid) (PGA), poly (lactic acid) (PLA), poly [lactic-co-(glycolic acid)] (PLGA), 
polyethylene glycol, chitosan, collagen, hyaluronic acid and alginate, have been widely 
used in the tissue engineering of cartilage, bone, skin, and ligament [4]. Collagen, drugs 
or constructs can be contained in therapeutic or diagnostic systems and are comprised of 
biologically derived components (amino acids or peptides). The research pays focuses on 
natural rather than synthetic polymers for bone tissue applications due to its higher 
biocompatibility and biodegradability [5]. Furthermore, these polymers contain an 
extracellular substance “ligand” which allows specific cell receptor interactions. It has 
been demonstrated that polymer structure can guide the growth cell at different stages of 
development and at the same time, stimulate an immune response. Among the polymers, 
chitosan and its derivatives represent very attractive candidates in scaffold composites, 
thanks to their degradation behaviour. In fact, chitosan degrades as soon as new tissue is 
formed without inflammatory reactions or toxic degradation [6, 7]. Moreover, chitosan 
(CS) is more widely used because of its ability to create porous natural scaffolds, its 
biodegradability and adsorption properties. Because its structure is similar to the 
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glycosaminoglycan in the extracellular matrix of bone and cartilage, CS has been used in 
bone tissue engineering [8]. From a chemical point of view, it is an amino-cationic 
polysaccharide derived from the partial deacetylation of chitin, a component in the 
exoskeleton of crustaceans [9] (Figure 2). Its chemical properties allow cell adhesion and 
proliferation, including osteoblasts [10-11], fibroblast, keratinocyte and endothelium cells 
[12]. 
According to several studies, it has also been reported that CS induces a great response in 
macrophages and neutrophils both in vitro and in vivo systems [13]. Additionally, the 
presence of the N-acetylglucosamine moiety on CS also suggests related bioactivities. It 
has been shown that CS oligosaccharides have a stimulatory effect on macrophages and 
both chitosan and chitin are chemo-attractants for neutrophils in both vitro and in vivo 
[14]. Moreover, the literature demonstrates host tissue response to CS-based implants. 
Generally, CS biomaterials exhibit a minimal foreign body reaction, with little or no 
fibrous encapsulation [15]. Furthermore, CS in vivo implantation in vertebrates has 
demonstrated that it may act as a substrate, which enhances specific types of progenitor 
cells (i.e. osteoblast differentiation), migration and differentiation [16]. This property is 
probably due to the ability of CS to be moulded into various shapes as well as its porous 
structure [17]. Nowadays, considerable research effort is being dedicated to improving 
the bioactivity and biological properties of CS scaffolds through the incorporation of a 
bioactive solid signal, such as hydroxyapatite (HA). Biomineralized materials can be 
produced in different ways; one way concerns the use of an inorganic biomimetic 
treatment, which comprises the precipitation and creation of apatite nucleation sites using 
a simulated body fluid (SBF) [18]. The natural hydroxyapatite and chitosan composites 
have good tissue biocompatibility and also excellent osteoconductivity. However, these 
materials are lacking when it comes to mechanical properties. To overcome this 
drawback, in this study the development of semi and grafted interpenetrating polymer 
networks based on poly(ethylene glycol) diacrylate (PEGDA) and chitosan was 
considered. The quickness of the reaction results from the presence of the double acrylate 
groups, which are able to react in the presence of free radicals. Furthermore, PEGDA 
polymer exhibits higher solubility in water and water solutions. Finally, it possesses 
specific chemical, mechanical and biological properties, which allow the use of PEGDA-
based systems in a wide range of biomedical applications (e.g., drug delivery vehicles, 
tissue engineered scaffolds and in vitro applications). The most widespread foaming 
techniques are salt leaching, gas foaming, phase separation, freeze-drying and 
 36 
 
electrospinning [19]. CS-PEGDA based porous scaffolds were developed through a 
foaming method [20]. The approach is based on the combination of two consecutive 
steps: 1) physical foaming is induced using Pluronic as blowing agent; 2) the foaming 
continues in a microwave reactor until it is arrested by a chemical reaction, which 
stabilizes the porous structure. 
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Figure 2. Chitosan chemical structure. 
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The microwave-induced reaction allows a rapid and homogeneous heating of the sample, 
avoiding the typical drawbacks of a conventional oven-heating process. Moreover, this is 
beneficial for the creation of a uniform interconnected porous structure without the 
presence of gradients between the core and scaffold surfaces. At the end of the process, 
an interpenetrated network is obtained because CS does not participate in the crosslinking 
reaction. The influence of different process parameters, such as time, power of 
microwave curing, and the effect of washing in acetone have been qualitatively evaluated 
through infrared attenuated total reflectance (ATR-IR) analysis. In vitro degradation of 
CS-PEGDA-based scaffolds was investigated to evaluate thermal stability, pore 
morphology, structure and weight loss, as a function of degradation time [20]. 
The aim of the present study was to develop bioactivated CS-PEGDA scaffolds using 
two different approaches (organic and inorganic cues), prepared in collaboration with Dr. 
Christian Demitri of University of Salento, in order to evaluate their effect on cellular 
behaviour in terms of proliferation and their potential to promote osteogenic 
differentiation in human mesenchymal stem cells (hMSC). It is well known that bone is a 
highly vascularised tissue relying on the spatial and temporal proximity between blood 
vessels and bone cells, in order to maintain skeletal integrity. There is a close relationship 
between osteogenesis and angiogenesis processes [21]. In fact, bone defect repair remains 
a major clinical orthopaedic challenge. In this context, angiogenesis plays a pivotal role 
in skeletal development and bone fracture repair. For this reason, by combining therapies 
using mesenchymal stem cells, and endothelial cells with polymeric bioactive 
biomaterials, it is possible to promote osteogenesis and angiogenesis simultaneously. 
Biomaterials with angiogenic and osteoinductive properties are widely under evaluation. 
 
1.1 BMP-2 mimetic peptide 
During bone formation, osteogenic growth factors are continuously produced [22]. 
Among osteogenic growth factors bone morphogenetic proteins (BMPs) play a key role 
in osteogenesis regulation during bone remodelling. BMPs are multifunctional cytokines, 
which are members of the transforming growth factor-β (TGF- β) superfamily. 
Polypeptides include TGF- β, activins/inhibins, and BMPs. BMPs stimulate signalling 
molecules, which can induce de novo bone formation at orthotopic, and heterotopic sites 
and their osteoinductive potency make them clinically valuable as alternatives to bone 
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graft [23]. The BMPs are also widely distributed in non-skeletal tissues such as nerve, 
heart, kidney, gastrointestinal tract and lungs. Moreover, BMPs have a pivotal role in 
vertebrate and non-vertebrate organogenesis [24]. In fact, several studies have 
demonstrated that BMPs exert neuro, cardio and reno-protective actions. The term “bone 
morphogenetic protein” (BMP) was introduced to describe the substance(s) in the 
demineralized bone matrix. “Morphogenesis” means generation of form, the process of 
tissue and organ construction and assembly [25]. 15 BMPs are currently recognised 
(BMPs 1-15). The osteoinductive properties of endogeneous BMPs of various origin (e.g. 
murine, ovine, bovine, reindeer, primate and human) have widely been studied both in 
vitro and in vivo systems [26]. Human BMPs are now available more readily and in larger 
quantities due to the advent of recombinant DNA technology [27]. Bone morphogenetic 
proteins (BMPs) can be associated with scaffolds and/or cells for use in bone tissue 
engineering. The presence of BMPs has been found in extracts of demineralized bone 
matrix and they have the ability to induce ectopic bone formation in subcutaneous and 
intramuscular pockets of rodents [28-29]. However, BMPs induce differentiation of 
multipotent mesenchymal stem cells into both osteochondrogenic and osteoblast 
phenotypes [30-31]. BMPs can be classified into subgroups depending on their sequence 
homology, e.g., BMP-2 and BMP-4 belong to the BMP-2/-4 subgroup, BMP-5, -6, -7, 
and -8 belong to the osteogenic protein-1 (OP-1) group. Members of the BMP family 
promote the formation of bone and cartilage in vivo. Especially, BMP-2 and BMP-7, also 
called OP-1, are under evaluation for tissue engineering application and available as 
clinically approved recombinant human proteins [32]. BMP family proteins bind to type I 
and type II serine/threonine kinase receptors which can phosphorylate the cytosplasmic 
proteins. As doother members of the TGFβ superfamily, BMP signals activate the 
intracellular signalling molecules, Smad1, Smad5 and Smad8, through serine 
phosphorylation. Activated Smad proteins form heterodimers with the co-Smad and 
Smad4, and translocate to the nucleus, where they regulate target gene transcription [33]. 
BMP2 stimulates transcription of Runx2, the master regulator of osteoblast commitment 
and BMP2-activated Smad proteins collaborate with Runx2 to induce expression of other 
genes in differentiating osteoblasts, including osterix (Osx/Sp7), another bone-specific 
transcription factor. Several studies report that bone morphogenetic proteins (BMPs) 
initiate, promote and maintain osteogenesis and chondrogenesis [34]. It has been 
demonstrated that BMP-2 based treatments induce osteogenic differentiation, whereas 
BMP-7 stimulates a chondrogenic phenotype of MSCs [35]. Therefore, MSCs with BMPs 
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provide a tool for bone and cartilage tissue engineering. [36]. Protein-based biomaterials 
have emerged as powerful tools for tissue engineering applications. It is possible to 
incorporate a peptide derived from bone morphogenetic protein-2 (BMP-2) into a single 
material in order to assess its effect on different phenotype cells such as human 
mesenchymal stem cells. Several means of delivering BMPs to patients are undergoing 
evaluation including systemic administration, gene transfer and local matrix delivery 
vehicle implantation. Indeed, BMP-2 peptide, within the context of genetically 
engineered proteins, is a central morphogenetic regulator of osteogenesis able to 
accelerate osteogenic differentiation. The incorporation of BMP-2 peptide within the 
context of modular proteins is a successful strategy for engineering biomaterials for 
applications in bone tissue engineering. BMP-2 growth factor is a potent cue for 
promoting osteogenic differentiation and is approved by the Food and Drug 
Administration (FDA) for clinical use in the regeneration of bone defects. An attractive 
alternative in the use of soluble BMP-2 growth factor is incorporating BMP-2 peptide, 
which is known to promote bone regeneration into a scaffold material. BMP-2 peptide 
can be immobilized by covalent or specific binding on the surface of the material. 
Previous studies have shown that BMP-2 peptide in modular proteins accelerates 
osteogenic differentiation and supports hMSC proliferation. 
 
1.2 Angiogenesis and bone fracture repair 
Angiogenesis represents an  important area of  scientific research due to its involvement in 
various physiological and pathological processes [37]. Investigations into angiogenic 
mechanisms require in vitro experimental models that simulate the important steps of 
angiogenesis to assess therapeutic agents’ efficacy (that either up-regulate or down-
regulate specific angiogenic mechanisms). Currently, the interest in anti-angiogenic agents 
for the treatment of cancer is particularly prominent. Several in vitro models have been 
developed to study the angiogenesis process [38]. These models involve methods for the 
study of angiogenic biological response in terms of proliferation, migration and 
differentiation of endothelial cells. The establishment of a functional vascular system is 
crucial during organ development as well as during tissue repair. In fact, in newly 
forming bone blood vessels not only does it represent a source of oxygen and nutrients 
but it also supplies calcium and phosphate, the building blocks for mineralization. 
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Additionally, blood vessels in the bone marrow appear to perform a crucial role as a 
niche for both the bone-forming skeletal stem cells and blood-forming hematopoietic 
stem cells [39]. The connection between angiogenesis and osteogenesis is also evident 
during the healing of bone fractures, as a timely and coordinated angiogenic response is 
of vital importance for successful bone repair [40]. Increasing insight into the molecular 
and cellular processes orchestrating the angiogenic cascade may help in the development 
of new treatments for fracture healing, especially for clinical situations with a limited 
angiogenic host response such as large bone defects or fractures with severe soft tissue 
trauma. When an organism or tissue grows beyond a size where passive diffusion for the 
exchange of oxygen, nutrients and metabolic waste products becomes insufficient, the 
need for the development of a vascular system emerges. Angiogenesis is the process by 
which the organism establishes new blood vessels from pre-existing ones. Recent studies 
have highlighted the fundamental aspects of vessel formation, including vasculogenic 
assembly, vessel sprouting, lumen formation and vascular remodelling [41]. The 
sprouting of endothelial cells (EC) is the first event in a sequence of events during 
angiogenesis [42]. In a resting vessel, both endothelial and mural cells form a basement 
membrane around the vessel tube, preventing resident EC to migrate. When new blood 
vessels are needed in a growing tissue, local production of angiogenic growth factors is 
enhanced, which trigger the EC to degrade the basement membrane extracellular matrix, 
a process mediated by matrix metalloproteinases (MMPs). The action of these MMPs 
further fortifies the angiogenic response by releasing proangiogenic factors that were 
stored within the matrix. Attracted by the angiogenic signals, some EC become motile 
and express filopodia. These so-called tip cells form the leading front of the newly 
forming vessel; the trailing EC are called stalk cells. The key angiogenic factor, Vascular 
Endothelial Growth Factor (VEGF) stimulates tip cell induction and filopodia formation 
via VEGF receptor (VEGFR) signalling [43]. The filopodia on the tip cells ‘sense’ the 
environment for attractive cues, guiding the sprouts into stromal tissue. Stalk cells are 
equipped to form tubes and branches, mediated by their high proliferative capacity and 
the ability to stabilize the newly formed lumen. The priming of EC into tip or stalk cells 
is also dependent on the Notch signalling pathway, in close intimacy with VEGFR 
signalling. In tip cells, VEGF signalling enhances Delta-like protein 4 (Dll4) expression, 
a Notch ligand. Dll4 activates Notch signalling in the neighbouring EC, thereby 
preventing their switch to a tip cell phenotype and favouring a stalk cell phenotype. New 
vessel circuits are created via the interaction of two neighbouring tip cells (i.e. 
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anastomosis). These connections are then stabilized by several processes including the 
deposition of extracellular matrix, the recruitment of pericytes, reduced endothelial cell 
proliferation and increased formation of cell junctions [44]. In addition to the maturation 
of the endothelium, vascular branches are remodelled to match their rigidity to the local 
tissue needs. The timely formation of new blood vessels is a critical process during 
embryonic and foetal development [45]. In adults, angiogenesis occurs during 
physiological processes like wound healing, the menstrual cycle, and pregnancy but also 
in specific diseases such as intraocular neovascular disorders and tumourigenesis. As 
opposed to soft-tissue healing, bone can regenerate itself without the formation of fibrous 
scar tissue and hereby maintains its physiological and mechanical characteristics. Normal 
fracture healing in adults occurs through intramembranous or endochondral bone 
formation, closely mimicking skeletal development in the embryo [46]. Intramembranous 
ossification is characterised by the direct formation of bone by committed 
osteoprogenitor cells and mesenchymal stem cells (MSC) from the periosteum. During 
endochondral ossification, MSC differentiate into chondrocytes, which in turn produce a 
cartilaginous matrix. Consecutively, this matrix undergoes calcification and is eventually 
replaced by bone [47]. The scar-less regeneration of fractured bones through the 
endochondral pathway might be attributed to the avascular nature of the cartilage 
template. In fact, chondrocytes are metabolically well adapted to survive in poorly 
oxygenated regions and still produce the extracellular matrix needed for mineral 
deposition, and hereby likely contribute to optimal fracture healing. Despite the 
remarkable regenerative capacity of bone tissue, fracture healing fails in about 10% of the 
cases leading to delayed union or non-union. Adequate vascularisation has been shown to 
be critical for successful bone healing, along with the presence of osteoprogenitor cells 
and mechanical stabilization. Indeed, inappropriate blood vessel supply is a major cause 
of delayed union or non-union during fracture healing [48]. More precisely, when 
fracture is associated with large vascular injuries, the rate of impaired healing is as high 
as 46%, exceeding by far the global 10% non-union rate [49]. In addition, inhibition of 
angiogenesis during fracture repair in animal models resulted in the formation of fibrous 
scar tissue, resembling human atrophic non-union [50]. Therefore, treatments promoting 
tissue vascularisation provide a central strategy to accelerate the healing response and 
tissue regeneration. It is evident that an adequate vascular response is needed for normal 
bone healing and the concept of therapeutic angiogenesis has been appreciated for many 
years. For successful tissue regeneration, it is necessary to understand the relations 
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established between different cell types involved in newly forming tissue [51, 52]. 
Indeed, most of the tissues require proper vascularisation and blood supply to support 
their functions. Alterations in the vascularisation process cause hypoxia at a cellular 
level, lack of nutrients, accumulation of waste products, impaired biochemical signalling 
and altered cell recruitment. This leads to the failure of tissue homeostasis and the 
inhibition of tissue regeneration [52, 53]. Therefore, the study of co-culture in vitro 
models consisting of osteogenic cell precursors and endothelial cells received more 
attention, in order to clarify vascularisation mechanisms. In the context of bone tissue 
engineering, endothelial cells, endothelial progenitors, osteoblasts or mesenchymal stem 
cells interactions are currently studied [52-54]. Indeed, the interaction between human 
umbilical vein endothelial cells (HUVECs) with primary osteoblasts demonstrated the 
formation of a vascular tissue-like network in vitro [55-56]. To provide successful 
substitutes for tissue and improve vascularisation in the local environment of the implant, 
pre/vascularised or endothelialised constructs were used [57]. Another valid possibility is 
the use of smart proangiogenic biomaterials, able to recruit endothelial progenitor cells. 
Angiogenesis and osteogenesis are intimately linked and it has been demonstrated that 
the processes need to be correctly regulated when bone regeneration occurs. This is also 
true for muscular tissue, given that its function depends on blood supply. In the specific 
case of bone, the formation of matrix starts with osteoblast-mediated collagen I 
deposition by forming osteoid, with the angiogenesis process occurring almost 
simultaneously. The matrix is gradually mineralized acquiring properties of mature bone 
[58]. Therefore, the angiogenesis process plays an important role in skeletal development 
and bone fracture repair. Indeed, the processes include the coordination of events such as 
migration, proliferation, differentiation and activation of many cell types (endothelial 
cells) [59]. The importance of blood vessels in the formation of the skeleton and in bone 
repair was documented in the 1700s [60]. Angiogenesis is the formation of new blood 
capillaries from pre-existing vessels [61]. Specifically, it is a physiological process for 
embryonic development, growth of organs and tissue repair. During development, wound 
healing and pregnancy, blood vessels respond to pro and anti-angiogenic factors involved 
in the process. An impairment of the process leads to abnormal growth of blood vessels 
and several human diseases, including tumour growth and metastasis, proliferative 
retinopathies, age-related macular degeneration, neo-vascular glaucoma, ischemia 
disorders and rheumatoid arthritis [62]. Since the function of three-dimensional (3D) 
scaffold tissue constructs depends on vascularisation after implantation, the analysis of 
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angiogenesis in tissue engineering is under investigation. For this purpose, in order to 
evaluate the effect on angiogenesis process, several in vitro and in vivo models were 
carried out. Notably, in vitro models often attempt to mimic one or more steps of the 
angiogenic process, in order to assess whether and how materials can affect endothelial 
cell function. In this chapter, the interest was in evaluating the effects of chitosan scaffold 
materials on the angiogenesis process in terms of proliferation, migration and 
differentiation of endothelial cell precursors. In other words, the aim of this part of the 
thesis was to explore the angiogenic potential of chitosan scaffolds on endothelial cells. 
The materials previously described have been studied to assess their ability to induce an 
angiogenic cell response using HUVEC cells. 
 
 Aim 2.
The aim of the first part of this thesis was to bioactivate chitosan-based scaffolds, 
prepared in collaboration with Dr. Christian Demitri of University of Salento, using two 
different approaches based on inorganic (deposition of hydroxyapatite nanoparticles) and 
organic (BMP-2 peptide functionalisation) components for promoting stem cells’ 
osteogenic commitment and preventing inflammatory response. Additionally, the 
osteoinductive properties of scaffolds on MSC and their angiogenic potential on in vitro 
model obtained by using HUVECs, a well-known endothelial cell line, were evaluated. 
 
 Materials and methods 3.
3.1 Scaffold preparation 
Scaffold preparation was performed in collaboration with Dr. Christian Demitri 
(University of Salento) [20]. Briefly, CS scaffolds were prepared using a new method 
based on two different steps. In the first step of the process, chitosan solution or CS 
(Medium molecular weight, DD 75-85%) was prepared by dissolving chitosan in 0.1 M 
Acetic Acid (AA, 99%) solution (1.5%wt). The mixture was stirred for 1.5 hours, in order 
to obtain a homogeneous viscous polymer solution; then, fixed amounts of PEGDA (20 
and 40%w/V) (average molecular weight of 700 g/mol) were added to the CS solution 
and stirred for 1.5 hours. In this step, 2.2-Azobis [2-(2-imidazolin-2yl)propane] 
dihydrochloride was used as a thermoinitiator (TI). A selected physical blowing agent 
 45 
 
such as Pluronic F127 (0,4% w/w), was added and mixed at 800 rpm for 30 minutes, so 
that a homogeneous distribution of air bubbles in a stable form was obtained [62]. In the 
second step, the porous structures of the foaming at different concentrations of PEGDA 
were chemically stabilized via radical polymerization induced by heating the sample in a 
microwave (MTS 1200 Mega, Milestone Inc., Shelton, CT 06484). Some of the resulting 
samples were washed in acetone to evaluate the possible removal of unreacted PEGDA 
and dried in a vacuum oven at 45°C. The samples were described and summarized in 
Table 1. Different percentages of CS and PEGDA allowed CS-based scaffolds to be 
acquired at different compositions. 
 
Table 1. Composition of chitosan (CS)-polyethylene glycol diacrylate (PEGDA) foams 
 
SAMPLES 
 
% CS 
 
% PEGDA 
 
80CS20P 
 
80 
 
20 
 
60CS40P 
 
60 
 
40 
 
70CS30P 
 
70 
 
30 
 
3.2 Scaffold bioactivation by inorganic signals 
The semi-interpenetrating CS-PEGDA scaffolds (80CS20P, 60CS40P and 70CS30P) 
were bioactivated using a modified method described by Kokubo and co-workers [50]. 
The treatment is based on the use of supersaturated SBF solutions to stimulate nuclei 
formation and growth (Figure 2). In the present study, the pH solution was fixed at 7.4 in 
order to select interactions between decarboxylated groups (COO
-
) and Ca
2+
 ions.  The 
SBF volume was calculated with reference to the total material surface using a specific 
ratio of the exposed surface to SBF volume, as reported in the literature [63]. After the 
incubation time, all materials were gently rinsed in distilled water to remove excess ions 
and, then, dried overnight under a laminar flow hood. 
 
3.3 Scaffold bioactivation by organic signals 
The second approach for scaffold bioactivation is based on the use of a bioactive peptide 
of Bone Morphogenetic Protein (BMP-2). The 67-87 residue of the “knuckle” epitope of 
hBMP-2 (NSVNSKIPKACCVPTELSAI) was synthesized using microwave-assisted 
Fmoc solid phase peptide synthesis (SPPS). The resin support and all amino acids (AA) 
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were obtained from Inbios S.r.l. (Naples, Italy). Rink amide linker (0.4 mmoles; Iris 
Biotech GmBH) was attached to a Tentagel-S-NH2 resin (Iris Biotech GmBH) in a glass 
vial; 1mL of 0.45M HBTU in N,N-dimethylformamide (DMF) and 0.5mL of 33% 
DIPEA in DMF were added to the reaction vessel to activate the exposed amino groups 
of the resin and after each coupling step to activate the deprotected group of the coupled 
AA. The AA coupling was performed after stirring the reaction suspension for 7 min in a 
Microwave synthesizer (Power 13W; Temperature 60°C; stirring rate 900 rpm); the 
solvent was removed and the mixture was washed with DMF (Aldrich). The Fmoc-
protecting group was removed from the coupled AA by incubating the resin with 20% v/v 
piperidine in DMF for 3 and 7 minutes. Following the final AA coupling, the resin-bound 
BMP-2 peptide was washed several times with dichloromethane, methanol, and diethyl 
ether. Finally, BMP-2 peptide was cleaved from the resin support through the exposure to 
a solution composed by TFA 95%-TIS 2.5%-dH2O 2.5% mixture for 3 hours and 
precipitated in a cold diethyl ether by centrifugation for 5minutes at 6,000 rpm. The 
cleaved products were characterised by analytical HPLC and mass spectrometry (micro-
TOF; Burker), before and after purification by preparative HPLC. In our systems, peptide 
immobilization occurred between NH2_CS and COOHBMP2 with a molar ratio 1:0.007; 3.6 
and 1.4-µg peptide/mg scaffold was used for 80CS20P and 60CS40P, respectively. 
Moreover, for 60CS40P a molar ratio of 1:0.018 of NH2_CS and COOHBMP2 was also used 
to obtain scaffold with the same amount of peptide used in 80CS20P (3.6 µg peptide/mg 
scaffold) (see Table 2). In this study, the peptide amount was determined based on 
preliminary biological experiments performed on BMP-2 peptide at different 
concentrations. 
 
Table 2: Scaffold composition and amount of peptide loaded for bioactivation 
 
 
NH2_CS: COOHBMP2 
1:0.007 1:0.018 
80CS20P_BMP 
3,6µg peptide/mg 
scaffold 
- 
60CS40P_BMP 
60CS40P_BMP* 
1,4µg peptide/mg 
scaffold 
*3,6µg peptide/mg 
scaffold 
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3.4 Morphological investigation: Scanning electron microscopy (SEM) 
For each sample, the morphology of the cross-section was analysed with scanning 
electron microscopy (ZEISS EVO 40 (Carl Zeiss, Milano, Italy)) in low vacuum modality 
with an applied voltage of 25 kV. The dried samples were cut into slices using a surgical 
blade. The samples were placed on the SEM sample holder using double-sided adhesive 
tape and were observed without any further manipulation. 
 
3.5 In vitro degradation test 
The samples were incubated at 37°C for 6 weeks in phosphate buffered saline (PBS) 
solution (KH2PO4 0.0087 M, Na2HPO4 0.0304 M, NaCl 0.154 M, pH 7.5). After 1, 2, 4 
and 6 weeks, the samples were washed in distilled water and dried in a vacuum oven at 
45°C for 12 hours. At the end of each time-point, the weight loss percentage of each 
samples was measured using equation weight loss percentage (%) = [(w0 – wt)/w0] × 100 
where w0 is the initial dry weight, wt is the dry weight after t time of degradation. CS 
scaffold surfaces, before and after biomineralisation, were analysed by Scanning Electron 
Microscopy (SEM, JEOL 6310). For SEM analysis, the materials were mounted using 
double adhesive tape to aluminium stubs. The stubs were sputter-coated with gold to a 
thickness of around 15-20 nm. SEM analysis was performed at different magnification at 
a voltage of 10 keV. Energy dispersive x-ray spectroscopy (EDAX, Genesis 2000) 
analysis was used for a qualitative estimation of the Ca/P ratio. 
 
3.6 In vitro release study 
The peptide release profiles from scaffolds at different compositions (80CS20P, 
60CS40P) were determined in vitro by High Performance Liquid Chromatography 
system (HPLC, Agilent). The bioactive scaffolds with BMP-2 peptide were dipped in 
200µL sterile Tris buffer solution (pH=6.8) and kept in a shaking incubator (37 °C, 40 
rpm) for various time periods of  up to 4 weeks. At specific times, supernatant was 
collected and an equal amount of fresh medium was added to each sample. A quantity 
equal to 20 μL of the obtained supernatant was injected in a chromatograph equipped 
with a UV detector and a reversed phase column (Reprospher C18, 150 mm×4.6 mm, 
DR. MAISCH, GmbH). The mobile phase systems consisted of 90% water (A) and 10% 
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acetonitrile (B). The flow rate was 1.0 mL/min and the wavelength was set at 220 nm. All 
experiments were triplicated for each sample. 
 
3.7. Biological investigations 
3.7.1. In vitro cell culture 
Cell proliferation assays were performed on human mesenchymal stem cells (hMSC) 
obtained from LONZA (Milano, Italy). hMSC were cultured in 75 cm
2
 cell culture flask 
in Eagle’s alpha minimum essential medium (α-MEM) supplemented with 10% foetal 
bovine serum, antibiotic solution (streptomycin 100 μg/ml and penicillin 100U/ml, Sigma 
Chem. Co) and 2 mM L-glutamine. For all experimental procedures hMSCs at passages 
3, were used. Cells were incubated at 37 °C in a humidified atmosphere (5% CO2, 95% 
air). For cell proliferation, hMSC were plated at a concentration of 1.6 x 10
4
 in triplicate 
onto CS scaffolds sterilized with ethanol for 60 minutes. The cell proliferation was 
evaluated with Alamar Blue assay for 3, 7, 14, and 21 days of culture. Fluorescence was 
measured at 540 and 600 nm. During the experiment, the culture medium was changed 
every two days. 
 
3.7.2 Cell viability test on CS scaffolds 
The cell biocompatibility was evaluated by seeding hMSCs (5,000 cells) in triplicate onto 
neat scaffolds (80CS20P and 60CS40P) after biomimetic treatments (80CS20P_bio, 
80CS20P_BMP, 60CS40P_bio, 60CS40P_BMP, 60CS40P_BMP*). The medium in cell-
load scaffolds culture plates was removed after cultures for 3, 7, 14 and 21 days and in 
vitro cell viability was checked using Alamar Blue assay, in accordance with the 
manufacturer’s protocol. During the experiment, the culture medium was changed every 
2 days. The cellular attachment is the first step in evaluating the biocompatibility of 
hMSCs onto CS-based scaffolds with and without biomimetic treatment. Biological 
assays were performed using human Mesenchymal Stem Cells line (hMSCs) purchased 
from LONZA (Milano, Italy). hMSCs were cultured in 75 cm
2
 cell culture flask in 
Eagle’s alpha Minimum Essential Medium (α-MEM) supplemented with 10% Foetal 
Bovine Serum (FBS), antibiotic solution (streptomycin 100 µg/ml and penicillin 
100U/ml, Sigma Chem. Co) and 2 mM L-glutamine, without osteogenic factors. hMSCs 
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of passage 4 for all the experimental procedures were used and incubated at 37°C in a 
humidified atmosphere with 5% CO2 and 95% air. 
 
3.7.3 BMP-2 peptide biological activity 
The bioactivity of BMP-2 peptide was evaluated using solutions at different 
concentrations starting from 2.70 µM to 270 pM, on hMSCs (5,000 cells at 4 passage) in 
order to investigate their effect on cellular behaviour, in terms of proliferation and 
osteogenic differentiation. The analysis were performed at 1, 3, 7 and 14 days in α-MEM 
supplemented with 10% foetal Bovine Serum (FBS), antibiotic solution (streptomycin 
100 µg/ml and penicillin 100U/ml) and 2 mM L-glutamine. The cell proliferation was 
determined using an Alamar Blue assay (AbD Serotec, Milano, Italy) based on the 
metabolic activity of live cells. In the meantime, the osteogenic differentiation was 
evaluated measuring the alkaline phosphatase activity (ALP) in cultures of scaffold 
materials after 7, 14 and 21 days (SensoLyte pNPP ALP assay kit, ANASPEC, Milano, 
Italy). At the end of each interval, cultures were washed gently with PBS, followed by 
washing with cold 1X assay buffer (BD Biosciences, Milano, Italy). The ALP activity 
was evaluated onto the cell lysates (50μl), in that case the cultures were treated with 1X 
lysis buffer with 0.2% of Triton X-100. To correct the ALP values for the number of cells 
present on each scaffold, double stranded DNA (dsDNA) was measured using a 
PicoGreen®_dsDNA quantification kit (Invitrogen). First, 100µl of diluted 
PicoGreen®_dsDNA quantification reagent was added to 100µl of cell lysates in a flat-
bottomed, 96-well plate. Following 10 minutes of incubation, the fluorescence of 
PicoGreen® was determined at a wavelength of 520 nm, after excitation at 585 nm using 
a spectrophotometer (Victor X3, Perkin-Elmer, Italy). dsDNA was quantified using a 
calibration curve of l-dsDNA standard in 10 mM Tris, 1 mM EDTA, pH 7.5, buffer. Each 
experiment was performed three times in triplicate. The results of ALP activity were 
reported as nanograms of ALP normalized to the micrograms of total DNA content. ALP 
experiments were repeated twice, and three materials were used in each experiment. 
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3.8 Effect of scaffolds on hMSC: osteogenic differentiation  
 
3.8.1 Alkaline phosphatase expression 
Differentiation of hMSC was tested measuring alkaline phosphatase (ALP) activity in the 
cultures of CS-based scaffolds after 7, 14 and 21 days (SensoLyte pNPP ALP assay kit, 
ANASPEC, Milano, Italy). This pNPP assay is based on the ability of phosphatase to 
catalyse the hydrolysis of p-nitrophenyl phosphate (pNPP) to p-nitrophenol (Sensolyte 
pNPP ALP assay Kit, AnaSpec). The phosphatase activity was analysed on the lysed cell 
following the manufacturer’s protocol. In fact, at the end of each time point, cultures 
were washed gently with PBS followed by double washing with cold 1X assay buffer 
(BD Biosciences, Milano, Italy). For the extract cell layers, the cultures were lysed with 
1X lysis buffer with 0.2% of Triton X-100. The ALP activity was analysed on the lysed 
cell (50μl). Sample absorbance was measured in a 96-well plate at 405 nm. To correct the 
ALP values for the number of cells present on each scaffold, double stranded DNA 
(dsDNA), as a marker for the cell number, was measured using a PicoGreen®_dsDNA 
quantification kit (Invitrogen). First, 100μl of 200μl diluted PicoGreen®_dsDNA 
quantification reagent was added to 100 μl of cell lysates in a flat-bottomed, 96-well 
plate. Following 10 minutes of incubation, the fluorescence of Picogreen was determined 
at a wavelength of 520 nm after excitation at 585 nm using a plate reader (multilabel 
counter 1420 Victor, Perkin-Elmer, Italy). The quantification of dsDNA occurred 
according to a calibration curve of l-dsDNA standard in 10 mM Tris, 1 mM EDTA, pH 
7.5, and buffer. Each experiment was completed three times in triplicate. The results of 
ALP activity were reported as nanograms (ng) of ALP normalized to the micrograms (μg) 
of total DNA content. ALP experiments were repeated twice and three scaffolds were 
used in each experiment. The alkaline phosphatase activity of the hMSC seeded onto 
biomimetic, non-biomimetic 80CS20P and 60CS40P scaffolds was determined. 
 
3.8.2 Osteocalcin levels 
The effect of CS-based scaffolds on osteogenic differentiation of hMSCs was evaluated 
by measuring a later marker of differentiation, such as osteocalcin (OCN). Osteocalcin 
levels were measured at days 14 and 21 using a commercially available kit (Quantikine 
Human Osteocalcin Immunoassay R&D system, Italy) following the manufacturer’s 
 51 
 
instructions. hMSC cells were cultured on control scaffolds (80CS20P and 60CS40P) and 
after biomimetic treatments (80CS20P_bio, 80CS20P_BMP, 60CS40P_bio, 
60CS40P_BMP, 60CS40P_BMP*) in basal medium at 21 days of culture time. 
Quantitative levels of OCN secreted into the culture medium were determined using an 
enzyme-linked immunoassay kit following the manufacturer’s instructions. 
 
3.8.3 Effect of CS-based-scaffolds on inflammation 
In the present study, the effect of CS-based scaffolds on inflammatory response using an 
in vitro experimental model was investigated. To this end, hMSCs were plated onto 
scaffolds and in tissue culture plates at a density of 1*10
4
 cells/well in 96 multi-well 
plates. After 24 hours, inflammation was induced by using LPS at a concentration of 1 
μg/ml. At day 3 of stimulation interleukin 1β (IL-1β), interleukin-10 (IL-10) and nitrite 
levels were measured. Interleukin-1β (IL-1 β), interleukin-10 (IL-10) levels in cell 
supernatants were quantified using commercial ELISA kits (Affymetrix, eBioscience Srl, 
Milano) according to the manufacturer’s instructions. Nitrite levels (stable metabolites of 
nitric monoxide) were analysed using Griess assay. For this purpose, 100 µl of 
supernatant was transferred into a 96-well plate and an equal volume of Griess reagent 
was added to each well. The samples were incubated for 1 hour at RT and absorbance 
was detected at 550 nm using a microplate reader (VICTOR
TM
 X3 Multilabel Plate 
Reader, PerkinElmer). 
 
3.9 Effect of CS-based-scaffolds on angiogenesis 
This study was developed during my time at IBEC under the supervision of Prof. 
Elisabeth Engel. 
 
3.9.1 Isolation and maintenance of human umbilical vein endothelial cells 
(HUVECs) 
Human umbilical vein endothelial cells (HUVECs) were isolated from the umbilical cord 
and cultured according to van Wachem et al. [3]. After harvesting, cells were cultured to 
the third passage in tissue culture polystyrene flasks T75 cm
2
 pre-coated with a solution 
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of partially purified human fibronectin (Fnc, 2 mg/ml) in a humidified atmosphere of 5% 
CO2 at 37°C and 95% air. EndoGRO
TM
 medium for human endothelial cell culture was 
used. The medium contained 0,2% ENDOGRO-LS supplement, 5ng/ml rhEGF, 10 mM 
L-glutamine, 1.0 mg/ml hydrocortisone hemisuccinate, 0.75 U/ml heparin sulfate, 50 
mg/ml ascorbic acid, 5 % FBS. HUVECs, used for subcultures and for experiments were 
detached by incubation with trypsin (Gibco, 0.05 % trypsin with 0.02% EDTA in PBS). 
Residual trypsin was inactivated by addition of culture medium. 
 
3.9.2 HUVECs proliferation 
To evaluate effects on angiogenesis process, human umbilical vein endothelial cells 
(HUVECs) at passage 5 were used for experiments. 70CS30P based scaffolds were 
prepared for cell seeding by soaking them in 70 % ethanol (24 hours) under UV-ray and 
then pre-wetting them in medium (2 hours). The experiments were performed using 
EndoGRO
TM
 medium products for human endothelial cell culture. The cell proliferation 
was checked by using Quanti-IT PicoGreen® DsDNA reagent and kits (Invitrogen). 
HUVECs were cultured at density of 1x10
3
 cell/well onto CS-based materials for 1, 3 and 
7 days of cell culture. 
 
3.9.3 Live-dead assay 
An in vitro qualitative analysis of cell viability with live/dead assay (Invitrogen) was 
performed. HUVECs were seeded at a density of 1 x 10
3
 cells in a 48-well plate and 
incubated at 37 °C in a humidified atmosphere with 5 % CO2 and 95 % air. The assay 
allowed living cells to be distinguished from dead cells. The staining was done using 
calcein AM/propidium iodide. Calcein AM stained living cells in green, propidium iodide 
stained dead cells in red. Chitosan 70CS30P samples were put in contact with 
ENDOGRO medium for an incubation time of 24 hours. After this incubation period, 
conditioned medium was added to cells for 24 hours. At the end, the non-attached cells 
were removed and carefully rinsed with PBS 1X three times. The cells were incubated 
with 2.5μl of calcein AM and 10 μl of propidium iodide for 15 min 37°C. Subsequently 
cell culture was washed with phosphate buffered saline (PBS1X) three times. The cell 
morphology and cell spreading pattern interaction of HUVECs in contact with materials 
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was evaluated with confocal laser scanning microscopy (LSM510, CarlZeiss) or a 
fluorescent microscope. Images of two sites per well with microscope and digital camera 
with a 10X phase contrast objective were taken. 
 
3.9.4 Calcium release 
To evaluate calcium release, 70CS30P materials scaffolds were washed three times with 
phosphate buffered saline (PBS) and put in 96 multi-well plate with EndoGRO
TM
 and 
DMEM 1X medium. The day after, CS conditioned media were collected and cleared 
with centrifugation. Resulting supernatants were assessed with Ortho-Cresolphthalein 
complexone (CPC) method to investigate released calcium concentrations at 1 and 4 days 
of incubation time as previously described [52]. 
 
3.9.5 Cell migration: scratch wound assay 
The migration capability of human vein endothelial cells (HUVECs) was assessed using a 
scratch-wound assay, which measures the migration of cells in a wounded area. To 
evaluate the effect of different conditioned media on cell migration, a scratch-wounded 
HUVECs monolayer was employed. Briefly, cells were seeded into 12-well tissue culture 
to confluence using ENDOGRO medium. Confluent HUVECs were scrape-wounded 
using a sterile p200 pipette tip for one perpendicular linear scratch. A blank line 
perpendicular to the scratch, painted under the bottom of the plate, ensured recording of 
the same wound area per well. Wells were washed with phosphate buffered saline (PBS 
1X) to remove floating and dead cells and conditioned media was added. Wound closure 
was monitored collecting digitalised images immediately after the scratch and 4 and 18 
hours afterwards. Images of two sites per well with an inverted microscope (Nikon 
TE200) and digital camera (Olympus DP72) with a 5X phase contrast objective lens were 
captured. Three representative images from each well of the scratched areas under each 
condition were photographed to estimate the migration cells. The reduction of wound 
areas was analysed using Image J1.48i software. Four replicates per condition were used 
and the experiment was repeated three times. 
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3.9.6 In vitro Matrigel-based formation assay 
In vitro tube formation assay is considered as representative of a later stage of 
angiogenesis and is widely used to assay potential stimulators or inhibitors of 
angiogenesis. Tube formation was determined in 48-well plates coated using Matrigel 
(Corning®) for 1 hour at 37 °C. HUVECs of passages 5 were harvested by trypsinization 
and seeded onto or within Matrigel. At the same time point, CS scaffolds conditioned 
media was added to the wells. The 48-well plates were incubated and the tubes formed at 
4 and 8 hours were observed under inverted phase contrast microscope (Leica). The 
presence of tube like-capillary structures indicated angiogenesis formation. 
 
3.10. Statistical analysis 
All quantitative experiments were performed in triplicate and the results were expressed 
as mean ± standard deviation (SD). Statistical analysis of the data was conducted using 
one-way ANOVA. Differences between the groups of p < 0.05 were considered 
statistically significant. 
 
 Results  4.
4.1 Scaffold preparation 
The foaming method used to prepare CS scaffolds by Dr. Demitri’s group [20], allowed 
an interconnected and homogeneous structure with pores of different size from 20 µm to 
300 µm and a hierarchical structure of the scaffolds to be obtained. This property allows 
the cells to migrate in the internal part of scaffold, while the micropores, due to solvent 
evaporation, manage nutrient flow and exchange of oxygen, avoiding the necrosis of 
cells. However, the presence of a second more rigid non-porous phase represented by 
PEGDA determines a decreasing of porosity [63]; in fact, an open porosity of 78% and 
60% for 80CS20P and 60CS40P, respectively. Measurements of water adsorption 
capacity report that there was no significant improvement in water absorption capacity by 
increasing CS concentration, probably owing to the higher capillary absorption effect, 
resulting from a homogeneous porous structure in each composition. The maximum 
swelling ratio was approximately 10.5 g/g, which was measured for sample 30P70CS. 
Rigidity of the scaffold, measured through a compressive test (carried out using the Ares 
 55 
 
rheometer), shows that scaffold with 40% PEGDA (60CS40P) has a higher Young’s 
modulus because of the presence of a second more rigid non-porous phase. Young’s 
modulus increased with the CS concentration, except in this sample, where the higher 
polymer density led to the presence of physical entanglements and a higher degree of 
cross-linking [64]. 
 
4.2 Scaffold bioactivation by inorganic signals: morphological analysis 
Following the scaffold production step, a bioactivation process was performed. 
Bioactivation is a simple two-step biomimetic approach, which consists of a nucleation 
phase obtained by incubation of scaffolds in a supersaturated SBF solution for 3 days, 
followed by a crystallisation and growth of apatite nuclei in a modified solution without 
inhibitors of crystallisation, such as hydrogen carbonate and magnesium ions. SEM 
images suggested the presence of calcium phosphate deposits on the scaffold surface and 
on the internal pore walls, after only 7 days of treatment (Figure 3). This behaviour was 
due to the use of two specific parameters represented by a supersaturated concentration 
(5xSBF) and pH value, in fact, at 7.4 the CS polymer shows a negative charge due to the 
deprotonation of COOH groups (pKaCS = 6.5). In this way, interactions between two 
COO
-
 groups and bivalent Ca
2+
 were favoured. 
 
4.3 Scaffold bioactivation by organic signals and in vitro release study 
The microwave-assisted Fmoc solid phase peptide synthesis allows a peptide to be 
obtained in a shorter time than through the conventional synthesis process, with a 
molecular weight of 2074,4 Da and high purity (>98%), as demonstrated by chemical 
characterisation through mass spectrometry and analytical HPLC, respectively (Figure 
4A). The pure peptide was immobilized on CS scaffolds (80CS20P and 60CS40P) 
(Figure 4B) by carbodiimide reaction mechanism, where the -NH2 groups of CS and -
COOH groups of BMP-peptide were involved. This covalent bond guarantees an in vitro 
release for an extended time. Particularly, the results onto 80CS20P scaffolds 
demonstrated a burst release of about 8-10% the first time (Figure 4C), due to an early 
scaffold degradation; however, the release was sustained up to 4 weeks where 80CS20P 
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released about 94.5% of peptide. In the case of 60CS40P_BMP scaffolds, with a higher 
amount of BMP2 mimic peptide (3.6µg/mg scaffold), a slower release in the first 48 
hours was obtained, probably due to a much more stable structure for the higher amount 
of PEGDA, compared to the 80CS20P samples; however, up to 4 weeks 60CS40P_BMP 
and 60CS40P_BMP* did release 97.3% and 92.9% of peptide, respectively. 
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Figure 3. Representation of biomineralization of CS-based-scaffolds. The process 
consists of nucleation and crystallization. Biomineralization obtained with hydroxyapatite 
(HA) deposition was performed using a supersaturated solution (5xSBF). 
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Figure 4. (A) Chemical characterisation of BMP2-peptide by HPLC and TOF mass 
spectrometry; (B) SEM images show the covalent immobilization of peptide on scaffold 
surface; (C) Peptide release profiles from 80CS20P and 60CS40P scaffolds. 
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4.4 Biological properties 
4.4.1 Biological activity of BMP-2 mimic peptide 
The bioactivity of neat peptide was investigated by measuring its effect on hMSCs 
behaviour in terms of proliferation and differentiation. First, the effect of peptide at 
different concentrations on hMSCs adhesion was determined after 1 day of cell culture. 
The LSCM images (Figure 5A) demonstrated that the cells in contact with solution at a 
higher concentration (2.7µM) showed a polygonal morphology typical of phenotype 
more similar to osteoblast than the control (CTR), whereas at lower concentration (270 
pM) the cells showed a fibroblast-like morphology as compared to the control. 
Furthermore, quantitative analysis about the cell proliferation (Figure 5B) proved an 
increased proliferation in the first 3days, followed by a decrease, due to initial osteogenic 
differentiation. In fact, a higher ALP value at 7 days (Figure 5C) was observed, 
particularly for the hMSCs in contact with solution at higher concentrations. This 
preliminary study was used as a screening to help determine the optimal concentration of 
BMP-2 peptide necessary for scaffold bioactivation; the results showed that 2.7µM 
solution had the best biological performance. 
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Figure 5. Confocal images of hMSCs after 24 hours of cell culture with BMP-2-peptide 
at different concentrations. BMP-2 at concentration of 2,7 μM induces the best biological 
response in terms of cell morphology. Polygonal morphology suggests osteogenic cell 
differentiation. 
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4.5 Viability test of bioactive CS-based scaffolds 
 
The effect of 80CS20P and 60CS40P scaffolds with and w/o BMP-2 mimic peptide (2.7 
µM) on hMSCs was also evaluated. The analysis demonstrated that, at 24 hours, there 
was good cell attachment on the scaffold surface with higher values for the biomimetic 
scaffolds at different compositions (Figure 6). After this time, the proliferation increased 
over culture time. This evidence confirmed that the scaffolds support adhesion and cell 
migration inside the scaffold structure. The proliferation showed higher values at day 14 
(Figure 7). On the other hand, at day 21 a slight decrease for the scaffold with the highest 
amount of BMP peptide (60CS40P_BMP*) was observed. 
 
4.6 Osteogenic differentiation 
4.6.1 Alkaline phosphatase and osteocalcin expression  
To study the effect of CS-based-scaffolds on osteogenic differentiation, the expression of 
alkaline phosphatase (ALP) and osteocalcin (OCN), was evaluated. The early osteogenic 
differentiation of hMSCs was tested measuring alkaline phosphatase (ALP) activity in 
cultures of scaffold materials after 7, 14 and 21 days (SensoLyte pNPP ALP assay kit; 
ANASPEC, Milan, Italy). The experiments were performed in basal medium considering 
the inorganic and organic bioactive signals as osteoinductive factors. Results showed that 
scaffolds with BMP-2 like peptide (80CS20P_BMP) do induce higher ALP values than 
biomineralized scaffolds (80CS20P_bio), even if 80CS20P_bio showed better results 
than neat 80CS20P. Furthermore, the scaffolds with lower amount of CS bioactive with 
BMP-2 like peptide (60CS40P_BMP and 60CS40P_BMP*) showed highest ALP values 
at day 3, probably due to the lower release profile of peptide in the first 48 hours and a 
higher scaffold stability (as demonstrated in the kinetic release study reported in the 
Figure 4). However, a higher ALP expression for the full set of scaffolds and, 
particularly, 80CS20P_bio was observed. Moreover, 80CS20P_BMP showed a similar 
behaviour to 60CS40P scaffolds (both 60CS40P_bio and 60CS40_BMP) at day 3. 
60CS40P_BMP* showed the best results over the culture time (Figure 9B). This 
behaviour was also observed for the expression of non-collagenous bone ECM protein 
(i.e. osteocalcin) used as later marker of osteogenic differentiation (Figure 10). 
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(A) 
 
(B) 
 
 
Figure 6. (A) Cell proliferation and (B) alkaline Phosphatase activity at different time 
points up to 14 days of cell culture. Results on cell proliferation and differentiation 
confirmed that the optimal concentration of BMP-2 is 2,7 μM. 
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Figure 7. Cell adhesion, expressed as percentage of control, of hMSCs seeded onto CS-
based-scaffolds (80CS20P and 60CS40P w/wo BMP-2 mimic peptide) after 24 hours of 
cell culture. 
 
 
 
 
 
 
80
C
S2
0P
80
/C
S2
0P
_B
IO
80
C
S2
0P
_B
M
P
60
C
S4
0P
60
C
S4
0P
_B
IO
60
C
S4
0P
_B
M
P
60
C
S4
0P
_B
M
P*
0
50
100
150
200
Day 1
%
 c
e
ll 
a
tt
a
c
h
m
e
n
t
 64 
 
 
 
 
 
 
 
 
 
 
Figure 8. Cell proliferation evaluated through Alamar Blue test. An increase in cell 
proliferation for bioactivated and non-bioactivated CS-based-scaffolds for up to 21 days 
of cell culture was obtained. Results, expressed as a percent reduction of Alamar Blue 
solution, are the mean ±SEM of three experiments.
 *
p<0.05, 
#
p < 0.01–0.001 vs. control 
(80CS20P-60CS40P). 
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(A) 
 
(B) 
Figure 9. Alkaline Phosphatase activity normalized to micrograms of DNA 
(ngALP/µgDNA) at short (A) and long-time (B). Results are mean ±SEM of three 
experiments. *p<0.05, #p < 0.01–0.001 vs. control. 
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Figure 10. Osteocalcin expression of CS-materials at day 21 of culture time. Results, 
expressed as osteocalcin levels (ng/ml), are the mean ±SEM of 3 experiments. 
*
p<0.05, 
#
p 
< 0.01–0.001 vs. control. 
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4.7 Effect of CS materials on inflammation: in vitro model 
LPS significantly increased the levels of IL-1β, a pro-inflammatory cytokine at the 
concentration of 1μg/ml. A pre-treatment of CS-based scaffolds with and without two 
(inorganic and organic) types of bioactivation counteracted the changes in IL-1β observed 
in cells treated with LPS alone (Figure 11A–B). In contrast, the levels of IL-10, an anti-
inflammatory marker, were significantly increased only in presence of the biomineralized 
80CS20P scaffold (Figure 11C-D). Furthermore, LPS (1μg/ml for 72h) stimulation 
caused a significant increase in the nitrite production (Figure 12A-B). However, a pre-
treatment with biomineralized 80CS20P induced a significant reduction in nitrite 
production. The inhibitory effect of the biomineralized 80CS20P scaffold on nitrite 
production in LPS-treated hMSCs was accompanied by a reduction in IL-1β and an 
increase in IL-10 levels. These results suggested that the biomineralized 80CS20P 
showed the best effect in terms of anti-inflammatory response on a model of bone 
inflammation. 
 
4.8 Effect of CS on angiogenesis 
4.8.1 Calcium release from CS-based-scaffolds 
Calcium released from CS-based-scaffolds by using O-Cresolphthalein complexone 
method was assessed. Preliminary study suggested that CS materials do not contain 
cytotoxic calcium concentration for HUVECs. In addition, data showed that CS bioactive 
and non-bioactive scaffolds contain a lower calcium amount than DMEM 1X (Figure 
13A) and ENDOGRO medium (Figure 13B). This behaviour could be explained by 
chitosan’s high adsorptive capacity. 
 
4.8.2 Live-dead assay 
In vitro qualitative analysis of cell viability with live/dead assay (Invitrogen) was 
performed. Preliminary, ENDOGRO medium by 70CS30P based-scaffolds through 24 
hours of incubation was conditioned and added to HUVECs. Microscopy images of 
70CS30P based-scaffolds showed that medium conditioned with bioactive CS materials 
does not compromise HUVECs survival thus inducing a better cell spreading compared 
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to medium conditioned with neat chitosan scaffolds (Figure 14). Moreover, a difference 
in HUVECs morphology between different CS samples was observed. In particular, CS 
bioactivated with BMP-2 peptide confers a different HUVECs morphology than other 
samples. This effect is probably due to the activation of proteins involved in cell 
differentiation such as VE-cadherin which induces an increase in HUVECs permeability 
[65]. 
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Figure 11. Effect of bioactive and non-bioactive CS-based-scaffolds on IL-1β (A-B) and 
IL-10β (C-D) levels in hMSC cells treated with LPS (1μg/ml). Measurements were 
performed 3 days after LPS (1μg/ml) stimulation. The exposure of hMSCs to CS-based 
scaffolds started 24 hours before the inflammatory insult. Results, expressed as 
picograms per ml of supernatant, are the mean ±SEM of three experiments. 
#
p < 0.01–
0.001 vs. control and 
§
p < 0.001 vs. LPS alone. 
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Figure 12. Effect of bioactive and non-bioactive CS scaffold on nitrite levels (A-B) in the 
cell medium of hMSCs incubated with lipopolysaccharide (LPS, 1 μg/ml) for 72 hours. 
The exposure of hMSCs to chitosan-based scaffold started 24 hours before LPS 
challenge. Results, expressed as nitrite concentration (nM), are the mean ± SEM of three 
experiments (in triplicates). 
*
p<0.05 vs. control and  
*
p < 0.05 vs. LPS alone. 
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(A) 
 
(B) 
 
Figure 13. Calcium concentration (mM) release from CS-based scaffolds using cell 
medium. The materials were conditioned with DMEM 1X (A) and ENDOGRO (B) 
medium for an incubation time of 1 and 4 days. The results, expressed as Ca
2+
 
concentration (mM) are the mean ± SEM of three experiments.*p<0.05, °p < 0.01 and 
#
p 
< 0.001 vs. control (ENDOGRO). 
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Figure 14. Fluorescent microscopic images of live-dead assay of HUVEC cells after 24 
hours of incubation on CS without bioactivation (A), biomineralized chitosan (B) and 
BMP-2 chitosan (C). Scale bar, 50 µm. 
 
C 
A 
B 
 73 
 
4.9 HUVECs proliferation 
Preliminary results in cell proliferation demonstrated that 70CS30P based-scaffolds 
increase HUVECs proliferation over culture time. However, the values are lower than the 
control plate, suggesting the potential effect of scaffolds on differentiation mechanisms 
(Figure 15). 
 
4.10 Cell migration: scratch-wound assay 
To evaluate the wound healing effect of 70CS30P samples on HUVECs an in vitro model 
was used. The experiment was performed with Mitomycin 10 μg/ml, as proliferation 
inhibitor, to promote migration rather than cell proliferation. Results obtained showed 
that the scratch assay is a convenient and inexpensive first method to measure cell 
migration, even if the scratch assay cannot substitute in vivo studies as a final proof of the 
efficacy in wound healing. This study confirmed the potential effect of CS biocomposites 
on HUVECs migration. Moreover, our results were also in line with tube formation data, 
which confirmed the effect of CS-based scaffolds on the angiogenesis process. Indeed, 
scaffolds ability to stimulate cell migration has been confirmed. These results indicated 
that both bioactive and non-bioactive scaffolds stimulate and support HUVECs migration 
(Figure 16). 
 
4.11 Tube formation quantification 
Angiogenesis involves the proliferation, migration, and remodelling of endothelial cells 
in the process of tube formation. HUVECs offer an important in vitro model to study 
these processes. Cultures of HUVECs on Matrigel, an extract of endothelial basement 
membrane, result in the formation of honeycomb-like structures that simulate tube 
formation of endothelial cells in vivo (19). Studying the effects of hypoxia, VEGF, FGF, 
and transforming growth factor-β and inhibitors of angiogenesis on the formation and 
organization of honeycombs by HUVECs has helped elucidate the mechanisms by which 
these factors regulate both pathological and therapeutic angiogenesis and the role of small 
GTP-binding proteins in this process. An important example has been the demonstration 
that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
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cholesterol lowering drugs, exert a dose dependent effect on honeycomb formation and 
signalling pathways in HUVECs suggesting that under appropriate conditions and at 
different concentrations, statins might both decrease the progression of atherosclerosis 
and stimulate the revascularization of ischemic tissues through its effect on angiogenesis 
[66]. A second model system for the study of angiogenesis has been the growth of human 
dermal microvascular endothelial cells (HDMECs), which are derived from the foreskins 
of newborns. When cultured on a thick collagen gel these cells form tube like structures 
that penetrate the collagen surface resembling capillary-like structures. To evaluate the 
later stages of angiogenesis in vitro tube formation assay was performed. Tube formation 
assay provides an in vitro model of tubulogenesis, which mimics in vivo conditions. For 
this reason, human umbilical vein endothelial cells (HUVECs) and Matrigel were used. 
As mentioned before, results demonstrated that chitosan 70CS30P based scaffolds induce 
tube formation in HUVECs at 4 and 8 hours of cell culture. Qualitative analysis confirms 
the possible use of chitosan materials for the promotion tube formation as shown in 
Figure 17. The potential angiogenic effect of the materials is enhanced by quantitative 
evaluation of HUVEC tube formation. In fact, chitosan scaffolds have a good effect on 
angiogenesis in terms of angiogenic parameters such as total tube length, branches and 
junctions quantification (Figure 18). Figure 17 shows the typical appearance of tubules on 
Matrigel for each CS-based-scaffolds at 4 and 8 hours of cell culture (CS alone, BMP-2 
and biomineralized CS) as compared to control and positive control (HUVECs and 
VEGF 20 ng/ml). Tubule development at 4 and 8 hours was observed and the extent of 
tubule formation was measured quantitatively using Angiosys 2 analysis program. 
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Figure 15. HUVEC proliferation was evaluated with PicoGreen assay. Cells were 
cultured on CS scaffolds for 1, 3 and 7 days of cell culture. Results, reported as DNA 
amount (ng/ml), are the mean ±SEM of three experiments. #p < 0.001 vs. control 
(HUVECs). 
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Figure 16. Effect of CS scaffolds on the migratory activities of HUVECs in the scratch 
assay in the presence of 10 μg/ml of antimitotic mitomycin C after 4, 8 hours of 
incubation (37◦C; 5% CO2) in ENDOGRO medium. Quantitative analysis of migration of 
human umbilical vein endothelial cells, in contact with CS scaffolds conditioned media, 
as compared to control (HUVECs), positive control (VEGF 20 ng/ml) was reported. Data 
are expressed as scratch area percentage (%) at 4, 8 hours in the wounded area 
normalized to 0 hours. Bars represent the mean ± S.E.M. of three experiments. #p < 0.001 
vs. control (HUVECs). 
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Figure 17. Microscopy phase contrast images of HUVECs tubules at 4 and 8 hours of 
cell culture of CS-BMP-2 (A), CS control (B), CS biomineralised with HA (C), HUVECs 
(D), VEGF 20 ng/ml (E). Scale bar, 100 µm. 
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             (A)                                   (B) 
 
 
(C) 
 
Figure 18. Quantification of HUVEC tube formation in CS-based scaffold conditioned 
media. Results, relative to cells growing on Matrigel, are expressed as a complete average 
of tube length (A), number of junctions (B) and branches (C), after 4, 8 hours of cell 
culture. Results are the mean ± SEM of three experiments (in triplicates). *p<0.05 vs. 
control (HUVECs). 
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 Discussion 5.
In bone tissue engineering the scaffold should provide necessary support as an artificial 
extracellular matrix that allows cells to proliferate and maintain their differentiated 
functions. Essentially, the scaffold acts as a temporary template to guide the formation of 
new tissue. In this context, an ideal scaffold is characterised by excellent 
biocompatibility, controllable biodegradability, cytocompatibility, suitable microstructure 
(pore size and porosity) and mechanical properties. Additionally, the scaffold must be 
capable of promoting cell adhesion and retaining the metabolic functions of the attached 
cells [49].For these reasons, the aim of this section of the thesis was to study the effect of 
biomimetic functional scaffolds obtained by modifying polymer scaffolds with 
osteoinductive signals including inorganic components, such as hydroxyapatite 
depositions and organic signals, such as BMP-2 mimetic peptide immobilized on the 
scaffolds with a covalent binding. Therefore, this research could help develop 
biodegradable scaffolds that are also carriers of osteogenic signals that promote positive 
cellular behaviour in terms of osteogenic commitment. To perform a covalent peptide 
immobilization on the scaffolds with different chitosan concentrations (80CS20P_BMP 
and 60CS40P_BMP)  a low percentage of burst release, 20% and 10% in the first 48 
hours, respectively is determined; whereas at longer intervals, a prolonged sustained 
release of up to 4 weeks has an important effect on cellular behaviour. The early effect of 
BMP in the first days of cell culture is due to the burst release of peptide, which 
continues over time, demonstrating the positive effect of prolonged delivery on cellular 
behaviour, because of the high stability of the scaffold structure (prepared by physical 
foaming combined with microwave curing) [55].  In vitro degradation tests showed a 
gradual dissolution of scaffolds over time, while maintaining their 3D morphology and 
integrity even after 6 weeks of incubation [20] and allowing an extended release of 
organic bioactive signal. This extended release potentially promises the successful 
infiltration of cells and new tissue formation. In fact, the biological results demonstrated 
that the materials act as support for hMSCs adhesion and proliferation. A consistent 
migration of cells into the scaffold is evident, as demonstrated in cross-section SEM 
images. Moreover, the effect of the organic and inorganic bioactive solid signals on 
osteogenic differentiation it was also evaluated and it was found that in vitro and in vivo 
may be characterised in three stages: (a) cell proliferation, (b) matrix maturation, and (c) 
matrix mineralization [56]. In vitro, matrix maturation and mineralization are usually 
enhanced by growing the cells to complete confluency and by adding specific osteogenic 
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factors. After the proliferation, the matrix maturation phase is characterised by an 
expression of alkaline phosphatase (ALP). ALP is a well-known early marker of 
osteogenic differentiaton and plays a key role in the mineralization of bone.  As such it’s 
considered a useful biochemical marker of bone formation [57]. Finally, during matrix 
mineralization (c) other genes for proteins such as OC, BSP, and OPN are expressed. 
Analysis of bone cell specific markers like Procollagen, ALP, OPN and OCN, is used to 
characterise later osteogenic differentiation phases in vitro of hMSC [58]. The 
mineralization process of osteoblasts in in vitro culture has also been used as a model for 
testing the effects of peptide loading on bone cell differentiation and bone formation. In 
this project, the expression of ALP and OCN were analysed; in particular, it was 
observed that at 3 and 7 days no difference was observed among the group of 
bioactivated scaffold and related controls (60CS40P and 80CS20P). Meanwhile, after 14 
days the best expression of ALP for the 80CS20P_BMP scaffold was observed, where a 
peptide release of approximately 65-75% (12-14µg) was obtained. In parallel, the 
60CS40P_BMP* showed the highest ALP expression at 21 days. On the other hand, 
biomineralized scaffolds developed through biomineralization treatment (80CS20P_bio 
and 60CS40P_bio) showed an increased ALP expression compared to materials that have 
not been biomineralized after 3 days of incubation. At the same point in time, similar cell 
differentiation behaviour, between 80CS20P_bio and 60CS40P_bio, was observed. At 
longer incubation times (7, 14 and 21 days), no significant difference between the two-
biomineralized groups and the BMP-activated scaffolds was observed. In particular, 
80CS20P_BMP showed  better ALP expression after 14 days than 
60CS40P_BMP/BMP*. After 21 days, the 60CS40P_BMP plateaued compared to levels 
at 14 days. On the contrary, the 60CS40P_BMP* sample at 21 days presents an increased 
ALP value compared to both 60CS40P_BMP and 80CS20P_BMP. The same behaviour 
was also detected for Osteocalcin expression (OCN) where the highest level was 
observed for scaffold with BMP2 mimic-peptide at day 21. This different behaviour 
could be explained by considering the difference in the ratio between the chitosan free 
amino groups (-NH2), and the induced carboxylic groups of BMP2 (-COOH). In fact, 
even if the cumulative release profiles showed no significant differences between the 
tested samples, the effect of the bioactivation appears in early osteogenic differentiation. 
This behaviour suggests that, by increasing the COOH/NH2 ratio, a positive effect on 
cellular behaviour is achieved. This trend can be explained by the specific interaction of 
peptide with the receptor on the cellular membrane which has significant effect on the 
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hMSC differentiation in the osteoblast phenotype. The phenomenon demonstrated that 
CS-PEGDA scaffold was a good carrier of peptide allowing a prolonged release over 
time, and maintained the local concentration of BMP2 mimic peptide at a good level, thus 
overcoming the drawbacks of some polymers used as carriers for the therapeutic agents 
delivery [59]. However, all samples showed significant positive effects on hMSC 
behaviour in terms of proliferation and osteogenic differentiation in basal medium, as 
evidenced by the expression of early (ALP) and later signals (OCN) of osteogenic 
differentiation in biomimetic and non-biomimetic scaffolds. Results have demonstrated 
that biomimetic scaffolds showed higher expression of OCN level and the best result was 
obtained for the scaffold bioactivated with BMP mimic-peptide, specifically for 
60CS40P_BMP*. Several clinical studies reveal that inflammation is a relevant disease as 
relates to osteoporosis , characterised by the production of inflammatory mediators 
including cytokines, histamine, bradykinin, prostaglandins, leukotrienes, PAF, biological 
response modifiers and the family of cell adhesion-promoting molecules [60]. Thus, 
immunological dysfunctions are determinant factors in the development and progression 
of osteoporosis and osteoarthritis. In fact pro-inflammatory cytokines such as (TNF)-α, 
interleukin (IL)-1β and interleukin (IL)-6 are elevated in pathological bone conditions 
and are responsible for cartilage and bone destruction [60]. Here we investigated the 
effectiveness of bioactive chitosan-based-scaffold on immune response modulation. To 
this end, not only pro-inflammatory cytokines such as interleukin (IL)-1β but also anti-
inflammatory cytokines such as IL-10 and stable metabolites of nitric monoxide as 
oxidative stress markers were assessed. Our studies suggested that bioactivated scaffolds 
were able to direct osteoinductive processes by preventing immune response induction. 
However, the best results in terms of anti-inflammatory effect were observed in 
biomineralized 80CS20P scaffold. The biomineralized 80CS20P scaffold demonstrated a 
complete profile as an anti-inflammatory agent inducing the inhibition of nitrite 
production (oxidative stress markers) in LPS-treated hMSCs accompanied by reduction 
of IL-1β (pro-inflammatory cytokine), while the biomineralized 80CS20P scaffold 
induced IL-10 production (anti-inflammatory cytokine) promoting bone formation. The 
engineering of bone tissue offers new therapeutic strategies for the treatment of many 
diseases, such as osteoporosis. Many scaffold constructs have been employed in the 
development of tissue-engineered bone; however, an active blood vessel network is an 
essential requisite for these to survive and integrate with existing host tissue. In recent 
years, generous attention was paid to processes such as angiogenesis, osteogenesis and 
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tissue engineering strategies, which could offer future therapeutic opportunities for 
skeletal repair and regeneration. For this purpose, the aim of this work was to assess, as 
preliminary study, the effect of different CS-based materials on angiogenesis. 
Angiogenesis is a complex multistep process consisting in the formation of new blood 
vessels from an existing vasculature. Furthermore, angiogenesis involves the degradation 
of extracellular matrix proteins and activation, proliferation, migration of endothelial 
cells and pericytes. It plays a pivotal role in physiological processes involving 
neovascularization, such as ovulation, placentation and embryogenesis. In addition, 
angiogenesis is correlated to several pathological processes, such as tumour growth and 
metastasis. A great interest was given to the study of molecules which can affect the 
process of  angiogenesis. To this end, human vein endothelial cell (HUVEC) based in 
vitro models  were used. In fact, we have used the HUVEC cell line as our model in order 
to study the potential effect of different CS samples bioactivated by different approaches 
on angiogenesis. In particular, the study is based on the evaluation of the effect of  CS 
porous scaffolds on HUVECs proliferation and viability. The angiogenic property of CS 
scaffolds composed of 70 % CS and 30 % PEGDA was evaluated in terms of cell 
proliferation, migration and tube formation. Angiogenesis was monitored in vitro by 
measuring the growth and migration of human vein endothelial cells (HUVECs) with 
media conditioned by CS-based scaffolds. Indeed, the work reports the in vitro 
cytotoxicity assessment of CS scaffold through live/dead staining of HUVECs. First, 
live/dead test was done as preliminary study in order to assess the cytotoxic effect of 
these samples on HUVECS. Results obtained from this study suggested that both neat 
and bioactivated scaffolds were not cytotoxic for HUVECs. Indeed, the materials do not 
compromise cell viability. Furthermore, HUVECs morphology changed in the presence 
of CS-BMP-2. This behaviour could be explained by the activation of many proteins 
involved in cell differentiation. Literature on the subject holds that BMP-2 stimulates 
endothelial cells promoting differentiation and tube formation. Indeed, BMP-2 induces 
phosphorylation of Erk-1/2, Smad 1/5, and increases Id1 expression. Erk-1/2 regulates 
several critical cellular functions in endothelial cells including proliferation and tube 
formation with expression of VEGF, epidermal growth factor, fibroblast growth factor, 
and angiogenin [61]. Additionally, many papers reported that BMP-2 and their receptors 
promote hyperpermeabilization of HUVECs by inducing internalization and c-SrC- 
phosphorylation of VE-cadherin which causes an increase in endothelial cell permeability 
[65]. Therefore, these data suggested that all CS materials were not toxic for cells and 
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that BMP-2 changes HUVECs morphology by stimulating the activation of cells and 
angiogenesis process. Starting from these data, our aim was to assess in vitro proliferation 
of HUVECs on all CS-based-scaffolds at 1, 3 and 7 days of cell culture. Results obtained 
by cell proliferation suggested that all CS scaffolds (with and without bioactivation) 
supported cell proliferation over culture time. The values for CS and CS biomineralized 
scaffolds were lower than for the control plate, because we compared two different 
systems: 2D (HUVECs) and 3D (scaffolds). Moreover, CS biomineralized scaffolds 
showed a higher proliferation than CS neat. This behaviour, probably, was due to a 
potential differentiation in HUVECs [63]. However, the preliminary results demonstrated 
the potential role of CS scaffold in the angiogenesis process in terms of HUVEC 
migration and tube formation. In fact, all CS materials conditioned media with Matrigel 
component were able to induce tubes formation. However, chitosan-BMP2 conditioned 
medium can also induced tubes formation without Matrigel after 18 hours of culture time. 
As reported in literature [64], bone Morphogenetic Protein-2 (BMP-2) has a crucial role 
in angiogenesis. In fact, it is highly over-expressed in the majority of patient-derived lung 
carcinomas and enhances the neovascularization of developing tumours. In fact, BMP-2 
induced tube formation in both HAEC and HUVECs. Moreover, BMP-2 also stimulated 
proliferation of HAEC. The ability of BMP-2 to activate endothelial cells was further 
demonstrated by its ability to phosphorylate Smad 1/5/8 and ERK-1/2 and to increase the 
expression of Id-1 [65]. 
 
 Conclusions 6.
This study has demonstrated the possibility of producing  biomimetic structures with 
highly interconnected and homogeneous structures with pores of different sizes from 
about 20 µm to 300 µm in agreement with the dimensional characteristics required for 
bone regeneration scaffold. The proposed technique holds strong potential for 
applications in the field of custom-made bone substitute. Moreover, the presence of 
bioactive signals on the scaffold surface allows an osteoinductive effect on hMSC to be 
obtained. Furthermore, the anti-inflammatory effects of bioactivated scaffold on a model 
of bone inflammation make the proposed scaffold a promising candidate for material for 
bone tissue regeneration as it also prevents a foreign body reaction (FBR). Finally, the 
materials also have a desirable effect on angiogenic response in terms of HUVECs 
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proliferation, cell migration and tube formation. In future studies, the synergic effect of 
combining organic and inorganic approaches to bioactivation could enhance every signal. 
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CHAPTER III  
Injectable ionic liquid-hydroxyapatite based biocomposites for 
bone defects 
 
1. Introduction 
An ideal device aimed at regenerating injured bone should possess a dual function as to 
stimulate the newly forming bone tissue and prevent bacterial infections. At present 
devices that are able to inhibit implant infections associated with biofilm formation have 
received considerable attention in the field of orthopaedic surgery [1]. This chapter 
describes the possibility of developing a multifunctional injectable material with 
antimicrobial and osteoinductive properties by using Ionic Liquids (ILs) as antimicrobial 
agents. 
 
1.1. Ionic liquids 
Ionic liquids are large organic cations, such as imidazolium or pyridinium, with alkyl 
chain substituents, which alter the molecules’ hydrophobicity. This class of chemicals is 
convenient for many applications, including the substitution of traditional industrial 
solvents and eradication of a wide range of microorganisms thanks to its antimicrobial 
activity. Particularly, ionic ILs are composed by cationic derivatives of the neutral 
imidazole heterocycles combined with (in) organic anions; this combination confers to 
these compounds a remarkable flexibility appropriate for designing systems with 
excellent physicochemical and biological properties. For this purpose, ILs can be applied 
as antimicrobial, antifungal, antitumour, antioxidant and anti-fibrous agents [2]. In 
addition, ILs can be used as solvents, catalysts in both industrial and academic sectors 
and can be combined with a wide variety of anions (inorganic or organic) thus considered 
task specific, because of their ability to be applied in a variety of manners. Substantially 
ILs, defined as green compounds, represent an alternative to common organic solvent due 
to low vapour pressures. In addition, several studies demonstrated the beneficial effects 
of ILs due to their features as vanishingly low vapour pressures, liquid state at ambient 
condition, and inability to evaporate as air pollution control [3]. Several studies reported 
that the introduction of a cleavable ester functional group in the side chain leads to a 
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significant increase in the biodegradability of the ILs molecules in comparison to those 
containing simple alkyl chains [4]. Long-chain imidazolium and pyridinium based ionic 
liquids consist of a charged hydrophilic head group and hydrophobic tail and 
consequently possess an inherent amphipathic nature. Previously, imidazolium and 
pyridinium derivatives with long alkyl chains have shown surface activity and biological 
activity. Also, ILs functionalized with ester chemical group seem to promote their 
biodegradability [5]. In the present study, ionic based liquids containing different carbon 
chain lengths were synthesized in order to investigate effects on cellular behaviour and 
antimicrobial activity. This research is expected to contribute to the further development 
of biodegradable improved ionic liquids as multifunctional compounds as well as to an 
assessment of their fate in the environment. Current investigations are focused on the 
antibacterial and antifungal effects of ILs-based compounds. Notably, these recent studies 
have demonstrated that an increase in the alkyl chain substituent in pyridinium or 
imidazolium leads to bacterial toxicity. In fact, it is possible to observe a higher toxicity 
in a wider spectrum of bacteria by increasing alkyl carbon chain. This toxic effect of 
several pyridinium and imidazolium compounds is explained by the hydrophobicity of the 
cation [6] and 1-n-hexadecyl-3-methylimidazolium methanesulfonate (C
16
MImMeS) 
have been identified as a good antimicrobial choice in hospital practice due to their 
effectiveness in inhibiting Candida biofilm formation when compared to chlorhexidine 
[7]. According to previous studies, ILs based compounds inhibit the biofilm formation of 
Staphylococcus Epidermidis and Aspergillus Niger in addtion to Candida Albicans thus 
resulting to be highly effective in therapies for keratitis [8]. The design of bone 
substitutes must combine antimicrobial and anti-inflammatory substances with bone 
precursors and it’s a considerable task. In order to achieve good osteogenic activity 
without the complications associated with bacterial infections many attempts have been 
made using a simple surface modification with biomaterials that mimic bone components 
[9]. Experimental evidences of P. Aeruginosa in vitro and in vivo have clearly 
demonstrated that biofilm bacterial cells are significantly more resistant to antibiotics and 
host immune defence than their planktonic counterparts.
 
Aggressive and intensive 
antibiotic treatment is usually helpful in controlling the exacerbations of chronic biofilm 
infections induced by dispersed bacteria and reducing the biofilms, but cannot eradicate 
biofilm infections,
 
because the minimal concentration of antibiotic for the eradication of 
mature biofilm is difficult to reach in vivo.
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1.2 Biofilm formation 
Once a bacterial biofilm infection established, it becomes difficult to eradicate. Bacterial 
biofilm formation (Figure 1) is widely found in natural environments with water, and in 
human diseases, especially in the patients with indwelling devices for the purpose of 
medical treatments. With the progress of medical sciences, more medical devices and/or 
artificial organs are applied in the treatment of human diseases. However, as a 
consequence, bacterial biofilm infections have also become frequent. It is reported that 
most of medical devices or prostheses which include intravenous catheters,
 
vascular 
prosthesis,
 
cerebrospinal fluid shunts,
 
prosthetic heart valves,
 
urinary catheters, joint 
prostheses and orthopaedic fixation devices,
 
cardiac pacemakers,
 
peritoneal dialysis 
catheters,
 
intrauterine devices,
 
biliary tract stents,
 
dentures,
 
breast implants, contact lenses
 
and in the dental area caries and periodontitis, and so on may result in biofilm infections,  
[10]. Additionally, there are also biofilm infections not associated with foreign bodies, 
such as chronic airway infections in cystic fibrosis (CF) patients or patients with chronic 
obstructive pulmonary diseases, native valve endocarditis, chronic otitis media,
 
chronic 
sinusitis
 
and chronic (diabetes) wound infections.
 
It has been estimated that most bacterial 
infections in humans are correlated with biofilm and about 50% of the nosocomial 
infections are indwelling device associated.
 
Bacterial biofilms are characterised as highly 
resistant to antibiotic treatment and immune responses. Although it is well-known that 
antibiotic treatment is currently the most important and effective measure for the control 
of microbial infections, however, it is almost impossible to eradicate biofilm infections 
with antibiotics. In vitro and in vivo experiments have demonstrated that the minimum 
inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) for 
biofilm bacterial cells were usually much higher (approximately 10–1 000 times) than for 
planktonic bacterial cells.
 
The effective antibiotic MBC in vivo for biofilm eradication is 
therefore impossible to reach by conventional antibiotic administrations due to the 
toxicities and the side effects of antibiotics and the limitation of renal and hepatic 
functions [11]. Treatment of biofilm infections has become therefore challenging and has 
attracted significant scientific attention. Numerous clinical investigations have been 
performed, which for the benefit of the control of biofilm. The work is focused mainly on 
the clinical treatment of bacterial biofilm infections with injectable materials based on 
calcium phosphate and ionic liquids. In this context, tissue-engineering based strategies 
for bone regeneration suggest the incorporation of various therapeutic agents such as 
antimicrobial, anti-inflammatory drugs and osteoinductive molecules in injectable 
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biomaterials [12]. Injectable biomaterials’ employment ensures advantages as compared 
to the use of non-injectable materials because of their ability for drug delivery thus 
promoting antibiotic and growth factors’ local release. Moreover, injectable biomaterials 
allow bone regeneration in a minimally invasive manner thanks to their remarkable 
plasticity [12]. Currently, the sol-gel method represents an effective technique for 
producing injectable bone substitutes and encapsulating therapeutic agents 
simultaneously. The method is very interesting because it allows encapsulating a wide 
class of thermosensitive compounds in biomaterials because precursors are mixed at 
lower temperatures than traditional methods [13]. Furthermore, organic-inorganic hybrid 
materials can be realized by using sol-gel approach. In particular, the sol-gel approach is 
very suitable for the synthesis of hydroxyapatite (HA)-based injectable materials due to 
the possibility to mix at molecular-level calcium and phosphorous precursors in order to 
obtain calcium phosphate (CaP) materials [14]. CaP based biomaterials are similar to 
bone in composition and form a uniquely strong interface with bone. Consequently, CaP 
triggers the newly forming bone as a precursor of biological apatite [15]. In general, 
biofilm forming on surface implant induces resistance to antibacterial agents, thereby 
contributing to bone destruction [16]. Indeed, the prevention of bacterial colonization and 
biofilm formation recieves considerable attention. It is evident from numerous studies of 
different systems that the use of antiseptic surface coatings is one approach to reduce the 
incidence of implant infection. Many previous investigations suggest implant 
modifications including the covalent attachment of polycationic groups, impregnating or 
loading nanoparticles with antimicrobial agents such as antibiotics, and coating the 
surfaces with quaternary ammonium compounds, iodine, and silver (Ag) ions [17].  
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Figure 1. Microbial biofilm formation. 
 
 
  
 95 
 
1.3 Calcium phosphate-ionic liquids injectable gels and tissue engineering 
applications 
An ideal bone substitute is aimed at regenerating injured bone should possess a dual 
function: to stimulate the newly forming bone tissue and to prevent bacterial infections. 
Many current researchers give more attention to those devices that are able to inhibit 
implant infections associated with biofilm formation in the field of orthopaedic surgery 
[8]. The structured consortium attached on living or inert surfaces formed by microbial 
cells and surrounded by the self-produced extracellular polymeric matrix is known as 
biofilm. Biofilm formation is considered an adaptation of microbes to hostile 
environments [8]. A typical development of biofilm includes several stages, i.e., 
attachment to a surface; formation of microcolonies; development of biofilm; 
differentiation of structured mature biofilm, and dispersal of mature biofilm. 
Biomaterials that possess both excellent osteogenic and antibacterial properties are thus 
crucially needed to overcome implant failure. Several approaches have been attempted in 
order to obtain antibacterial and osteogenic effects by using biomaterials functionalized 
with antimicrobial and osteoinductive agents. For example, Zn/Ag co-implanted titanium 
showed both excellent osteogenic and antibacterial activities and has strong potential for 
orthopaedic implants [9]. Currently, within these new approaches chemical engineers 
have been synthetizing a wide class of ionic liquids (ILs) as antimicrobial agents. Implant 
failures occur due to implant-associated bacterial infections and inflammation, which 
inhibit adequate osseointegration [8]. Furthermore, local bacterial infections may induce 
systemic pathologies, thus increasing the costs of hospitalization for patients. In fact, the 
costs for bacterial infection care raise the cost of implants used in many orthopaedic 
surgical procedures and complicate health management [10]. A higher toxicity in a wider 
spectrum of bacteria was observed. This toxic effect for several pyridinium and 
imidazolium compounds is due to the hydrophobicity of the cation [11]. In order to obtain 
antibacterial and osteoinductive effects, ILs can be combined with bone precursors. 
Recently, several studies have demonstrated that some biomaterials such as Poly (lactic 
acid) PLA can be improved by adding 1-methyl-3-n-pentylimidazolium and 1, 2-
dimethyl-3-n-pentylimi-dazolium ionic liquids on the surfaces. In the context of 
Candidemia, ILs-based materials showed antifungal activity against isolates of C. 
Tropicalis, C. Parapsilosis, C. Glabrata, and Trichosporon Asahii and these beneficial 
effect depend largely on the N-alkyl chain-length. Among these compounds, 1-n-
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hexadecyl-3-methylimidazolium chloride (C
16
MImCl) and 1-n-hexadecyl-3-
methylimidazolium methanesulfonate  (C
16
MImMeS) have been identified as an 
excellent antimicrobial choice for hospital practice, due to their effectiveness in inhibiting 
Candida biofilm formation when compared to chlorhexidine [12]. According to previous 
studies, ILs based compounds inhibit biofilm formation not only for C. Albicans, but also 
for Staphylococcus Epidermidis and Aspergillus Niger, therefore resulting to be highly 
effective in the therapy for keratitis [13]. In the design of bone substitutes, it is important 
to combine antimicrobial and antinflammatory substances with bone precursors. In order 
to achieve good osteogenic activity without the complications associated with bacterial 
infections, many attempts have been made using a simple surface modification of 
biomaterials, which mimic bone components [14]. Tissue-engineering-based strategies 
for bone regeneration suggested the incorporation of various therapeutic agents, such as 
antimicrobial, anti-inflammatory drugs and osteoinductive molecules in injectable 
biomaterials [10]. The use of injectable biomaterials ensures advantages as compared to 
the use of non-injectable materials, because of their ability for drug delivery, as well as 
promoting antibiotic and growth factors local release. Moreover, these injectable 
biomaterials allow minimally invasive bone regeneration, thanks to their remarkable 
plasticity [10]. Nowadays, the sol-gel method represents an effective technique for 
producing injectable bone substitutes and for encapsulating therapeutic agents 
simultaneously. This method also allows encapsulating in biomaterials a wide class of 
thermosensitive compounds, because precursors are mixed at lower temperatures than 
with traditional methods [11]. Furthermore, organic-inorganic hybrid materials can be 
realized using the sol-gel approach. Particularly, the sol-gel approach is very useful for 
the synthesis of hydroxyapatite (HA)-based injectable materials, due to the possibility of 
mixing at molecular-level calcium and phosphorous precursors in order to obtain calcium 
phosphate (CaP) materials [12]. It is known that CaP based biomaterials are similar to 
bone in composition, forming a uniquely strong interface with bone. On this basis, CaP 
triggers the newly formed bone as a precursor of biological apatite [13]. Generally, in 
implant infections biofilm induces resistance to antibacterial agents, thereby contributing 
to bone destruction [14]. Hence, the prevention of bacterial colonization and biofilm 
formation has garnered considerable attention. It is evident from numerous studies of 
different systems that the use of antiseptic surface coatings is one approach to reduce the 
incidence of implant infection. Many previous investigations suggest implant 
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modifications, including the covalent attachment of polycationic groups, impregnating or 
loading nanoparticles with antimicrobial agents, such as antibiotics, and coating the 
surfaces with quaternary ammonium compounds, iodine, and silver (Ag) ions [15]. The 
main goal of orthopaedics is the capacity for pain-relief as derived from function 
restoration and the correction of patients’ deformities through less invasive techniques. 
Pain is an important consequence of inflammation and infection induced by body-implant 
surface interaction. Innovation in the orthopaedic material sector can solve this issue, 
even if these new procedures might cause an increase in healthcare costs [16]. In order to 
obtain a multifunctional product able to inhibit infection and, at the same time, to induce 
osteogenic activity, in the present study we developed CaP based injectable materials 
containing a variety of 1-n-alkyl-3-methylimidazolium chlorides ILs (CaP, CaP_C4, 
CaP_C10, CaP_ (C10)2, CaP_C16) obtained with the sol-gel method. Specifically, the 
present work suggests the possibility of combining osteogenic enhancement and 
antibacterial ability in a single injectable material. The importance of this combination 
will be decided by its impact on future studies focused on the synthesis of more complex 
medical devices for bone tissue regeneration and the simultaneous prevention of biofilm 
formation. 
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2. Aim 
The aim of second part of this thesis was to develop injectable biomaterials consisting of 
ionic liquid loaded hydroxyapatite obtained with the sol-gel approach. The effect of ILs 
alkyl-chain length on crystallization of hydroxyapatite were tested. Biological effects in 
terms of osteogenic differentiation of hMSC and microbial proliferation were also 
evaluated. 
 
 Materials and Methods 3.
3.1 Synthesis of nanostructured IL-loaded calcium phosphates 
The CaP/IL gel injectable systems were obtained at room temperature using sol-gel 
technique. For the sol-gel synthesis, calcium nitrate tetrahydrate Ca (NO3)2·4H2O (99% 
A.C.S. Reagent, Aldrich) and ammonium phosphate dibasic (NH4)2HPO4 (A.C.S. 
reagent, Aldrich) were chosen as precursors of Ca
2+
 and PO4
3-
, respectively with a molar 
ratio Ca/P in the range 1.5-1.67. Before the synthesis process, IL [CnMIm]Cl (1-n-alkyl-3-
methylimidazolium) with different single chain-lengths (Cn= CnH(2n+1); n= 4, 10, 16) and 
double chain (C10)2MImCl were dried under vacuum for 3 hours at 60C and dissolved in 
a solution of distilled water (dH2O). Particularly, C4MImCl and C10MImCl were 
completely dissolved in dH2O, in the meantime C16MImCl and (C10)2MImCl were 
dissolved in a mixture of dH2O:DMSO (1:1), in order to obtain a complete dissolution of 
ILs. When Ca(NO3)2·4H2O was completely dissolved in dH2O, [CnMIm]Cl solution at a 
different composition (1 and 2wt%) was added to Ca
2+
 solution and stirred for 2 hours at 
40°C. Then, a PO4
3-
 solution was added dropwise to the system and pH was adjusted at 
alkaline value (pH equal to 11) by NH4OH. Gel transition took place after 1 hour of 
magnetic stirring at room temperature; furthermore, it was observed that the presence of 
[CnMIm]Cl induces shorter gelification times in comparison with the neat CaP system. 
After gelification, an ageing step of 2 days at 60°C for all systems with and without 
[CnMIm]Cl was performed. 
 
3.2 Morphological characterisation: TEM analysis 
The morphological distribution of ILs in CaP matrix and their effect on nanoparticle size 
were evaluated by Transmission Electron Microscopy (TEM) investigation. The analysis 
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was performed by a TEM FEI Tecnai G12 Spirit Twin model instrument operated at an 
accelerating voltage of 100 kW. Samples for TEM imaging were prepared by placing a 
drop of the aged IL/CaP suspensions (the IL-CaP gels were dissolved in dH2O and the 
obtained suspensions were diluted and dispersed by ultrasonic waves before use on 
carbon coated copper grids, dried in air and loaded into the electron microscope 
chamber). 
 
3.3 Antifungal and Antibacterial tests 
-Antifungal tests 
The Candida Albicans (ATCC 14053) and Candida Tropicalis (ATCC 13803) strains 
were grown in Sabouraud agar plates for 24 hours at 36.6 °C. Aliquots of 150 μL of 106 
colony-forming units per millilitre (CFU mL
-1
) were diluted in to 5mL of saline solution 
and then aliquots of 100μL of the second solution were again diluted to 2mL of RPMI 
medium. For the antifungal tests 500μL of the third solution were added to 500μL of a 
suspension (1 mg mL-1 in RPMI) of the investigated materials and incubated for 5 hours 
at 36.6 °C. The percentage calculation of surviving fungi was done by CFU counting 
after seeding 20 μL (drop method) of each test in Sabouraud agar plates, which were 
incubated for 24 hours at 36.6 °C. 
 
-Antibacterial tests 
A single colony of E. coli DH5α was taken from an agar plate grown overnight (18-
20hours) at 37 °C and transferred to 5 mL of Luria Bertani (LB) broth (containing 10 
g·L
−1
 peptone and NaCl and 5 g·L
−1
 yeast extract) and incubated overnight. The bacteria 
concentration was then determined by turbidimetry (OD600) and the solution was diluted 
to 108 CFU.mL
-1
. The antibacterial tests were performed via the overnight incubation of 
980 μL of LB broth, 20 μL of the 108 CFU.mL-1 bacteria solution and 1000μL of the 
materials’ aqueous suspension (1 mg.mL-1). The pure substance controls were performed 
by the addition of 1000μL of a 20ug.mL-1 of each ionic liquid. After incubation, the 
OD600 was measured for the positive control (bacteria growing without any material or 
substance) and all the tests were diluted to obtain a concentration of 2000 CFU mL
-1
 
based on the control. From the diluted solutions, 100μL were seeded to LB agar plates 
using automated plating equipment (Easy Spiral Dilute Interscience) and incubated 
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overnight at 37°C. The antibacterial effect was evaluated by CFU counting that was 
performed using ImageJ software. 
 
 Biological properties 4.
4.1 In vitro cell culture 
Biological assays were performed using human Mesenchymal Stem Cells line (hMSC) 
obtained from LONZA (Milano, Italy). hMSC were cultured in 75 cm
2
 cell culture flask 
in Eagle’s alpha Minimum Essential Medium (α-MEM) supplemented with 10% Foetal 
Bovine Serum (FBS), antibiotic solution (streptomycin 100 µg/ml and penicillin 
100U/ml, Sigma Chem. Co) and 2 mM L-glutamine, without osteogenic factors. hMSCs 
at passages from 4 to 6 were used for all the experimental procedures and incubated at 
37°C in a humidified atmosphere with 5% CO2 and 95% air. 
 
4.2 Cell adhesion and proliferation 
Cell adhesion was evaluated at day 1 using a quantitative colorimetric test, such as 
Alamar Blue assay. hMSCs (5,000 cells/well) were re-suspended in 50ul medium and 
plated on the surface of sterilized gel materials with and without ILs at different 
concentrations (1 and 2wt%). After 2 hours of cell culture, 500µl of medium was added 
and the gel materials were incubated overnight at 37°C. After this time, the medium was 
replaced with 500 µL of Alamar Blue solution (obtained by dilution 1:10 of 
alamarBlue™ reagent in DMEM w/o red-phenol) and added to each well and incubated 
for 4 hours at 37°C, 5% CO2. Then, 200µL of solution was transferred into a 96-well 
plate, in order to evaluate the absorbance at 540 and 600nm (Victor X3 
spectrophotometer, Perkin Elmer). Wells without any cell were used to correct any 
background interference from the redox indicator. The cell proliferation at longer 
intervals (3, 7, 14 and 21 days) was evaluated by quantifying the DNA amount by using 
PicoGreen dsDNA quantitation assay. PicoGreen® dsDNA Quantitation Reagent is an 
ultra-sensitive fluorescent nucleic acid stain used to quantify double-stranded DNA 
(dsDNA); fluorescence was measured in black 96-well plate at 480 nm. The dsDNA 
amount was determined by a standard calibration curve according to the manufacturer’s 
protocol. The culture medium during the experiment was changed every two days. 
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4.3 Alkaline Phosphatase and Osteocalcin expression as markers of osteogenic 
differentiation 
The effect of IL-CaP gels on osteogenic differentiation of hMSCs was evaluated by 
measuring early and later markers of differentiation such as Alkaline Phosphatase (ALP) 
and Osteocalcin (OCN), respectively. The phosphatase activity levels were tested on cell 
lysates (50µl) by measuring the activity of ALP enzyme, which catalyses the cleavage of 
a phosphate group and releases p-nitrophenol from p-nitrophenyl phosphate using the 
SensoLyteTM pNPP Alkaline Phosphatase Assay Kit (AnaSpec, DBA, Italy), according 
to the manufacturer’s instructions. The absorbance was measured in a 96-well plate at 
405 nm on a plate reader to determine enzyme concentrations per construct at 3 and 7 
days. The ALP values were corrected for the number of cells present on each material. In 
that case, double stranded DNA (dsDNA), used as a marker for cell number, was 
measured by using a PicoGreen_dsDNA quantification kit (Invitrogen, USA). The ALP 
results were reported as nanograms of ALP normalised to the micrograms of total DNA 
content (ng ALP/µg DNA). Furthermore, Osteocalcin (OCN) levels were measured at 
days 14 and 21 using a commercially available kit (Quantikine Human Osteocalcin 
Immunoassay R&D system, Italy), following the manufacturer’s instructions. 
 
4.4 Effect of IL-loaded CaP gels on inflammatory response 
The effect of IL-CaP gels on in vitro experimental models of inflammation and oxidative 
stress was also tested. To this end, hMSCs were plated onto scaffolds and tissue culture 
plate at density of 1x10
4
 cells/well in 96 multi-well plates. After 24 hours, inflammation 
was induced by using LPS at concentration of 1 μg/ml. At day 3 of stimulation 
interleukin-10 (IL-10) levels in cell supernatants were quantified using commercial 
ELISA kits (Affymetrix, eBioscience Srl, Milano), according to the manufacturer’s 
instructions. Nitrite levels (stable metabolites of nitric monoxide) were analysed by using 
Griess assay. For this purpose, 100 µl of supernatant was transferred into a 96-well plate 
and an equal volume of Griess reagent was added to each well. The samples were 
incubated for 1 hour at room temperature and the absorbance was detected at 550 nm 
using a microplate reader (VICTORTM X3 Multilabel Plate Reader, PerkinElmer). For 
ROS assay, hMSCs were plated in 96-well black costar plates (Corning, USA) at the 
density of 1×10
4
 cells/well and cultured onto materials for 72 hours at 37°C. The cells 
 102 
 
cultured on tissue culture plate were used as a control. After washing, cells were 
incubated for 1 hour with 200μl of 100 μM H2DCF-DA in HBSS containing 1% FBS. 
Then cells were incubated with Fenton's reagent (H2O2/Fe
2+ 
2 mM) for 3hours at 37°C. 
The intracellular ROS levels were expressed as fluorescence intensity, which was 
detected using a fluorescent microplate reader (excitation 485 nm and emission 538 nm). 
 
4.5 Statistical analysis 
All quantitative experiments were performed in triplicate and the results were expressed 
as mean ± standard deviation (SD). Statistical analysis of the data was conducted using 
one-way ANOVA. Differences between the groups with p < 0.05 were considered 
statistically significant. 
 
 Results 5.
5.1 Morphological Investigation: TEM analysis 
TEM investigations (Figure 2) showed changes in the nanoparticle size of the HA/IL 
systems and demonstrated the important role of the IL-structure in HA morphology. IL 
interacts with the growing particles through the hydrogen bond “co-π-π stacking” 
mechanism, which creates an IL-layer on the HA surface. Therefore, differences in the 
size, geometry, polarity and Coulomb coupling forces between ILs’ anions and cations, 
contribute directly to the final HA particle size and morphology. In addition, the 
hydrophobic tail-tail interactions of the IL with longer cation side-chains caused the 
formation of agglomerates larger than those in shorter alkyl chains.   
 
5.2 X-ray diffraction 
Figure 3A shows the XRPD patterns of the investigated HA/IL systems: the blue curves 
are the experimental data, the grey curves are the Rietveld fits and the red curves are the 
difference between the experimental and calculated profiles.  The qualitative analysis of 
each pattern has been carried out by the program QUALX2 [17] that allowed us to 
identify the crystalline phases that match the diffraction patterns: Hydroxyapatite (HA, 
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Ca10 (PO4)6(OH) 2), Monetite (CaHPO4) and Brushite (CaHPO4(H2O) 2). Through the 
QUANTO [18] program, performing Rietveld fits of the XRPD data, a quantitative 
determination of all the crystalline phase weight fractions for each sample was achieved 
(reported in Figure 3B). 
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Figure 2. TEM analysis of nanoparticles of HA with ILs at different carbon chain 
lengths.  
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(B) 
Figure 3. (A) Diffraction patterns in CaP-ILs powders. (B) Quantitative determination of 
all the crystalline phase weight fractions. 
CaP 
-control- 
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5.3 Antimicrobial investigation 
5.3.1 Antifungal and Antibacterial tests 
The antimicrobial study of fungi and bacteria highlighted the antifungal activity on C. 
Albicans and C. Tropicalis of the biocomposites with C10MImCl, C16MImCl and 
(C10)2MImCl.  At the same time, antibacterial tests showed positive properties for use in 
materials but the best performance in bacteria proliferation inhibition was obtained with 
(C10)2MImCl based biomaterial on E. Coli (Figure 4A-B).  
 
5.3.2. Biofilm formation 
SEM analysis (Figure 5) demonstrated the presence of biofilm formation on CaP alone 
and CaP with short-chain ionic liquid with no trace of biofilm on CaP with long alkyl 
chain as observed in  CaP_C10;CaP_C16; and CaP_(C10)2. 
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(A) 
 
(B) 
 
 
Figure 4. (A) Antifungal and (B) antibacterial tests. 
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Figure 5. SEM images of biofilm formation in CaP system.  
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5.4 Biological studies 
The effect of IL-loaded calcium phosphate gels on the cell behaviour was evaluated 
through some investigations concerning adhesion, proliferation, osteogenic differentiation 
and inflammatory response. Biological analyses were performed using human 
mesenchymal stem cells (hMSC), undifferentiated cells with the capability to 
differentiate into many cell phenotypes (i.e. fibroblast, osteoblasts, muscle, 
chondrocytes). In the research process, our interest was in evaluating the differentiation 
of hMSC in osteoblast phenotypes. Particularly, in order to evaluate the osteoinductive 
effect of IL-CaP materials on human cells, experiments in basal medium without the 
presence of osteogenic factors such as ascorbic acid, dexamethasone and β-
glycerophosphate, were performed. 
 
5.4.1 Cell adhesion and proliferation 
The results demonstrated that the presence of ILs in the CaP matrix improves the 
metabolic activity and cell attachment in the first 24hrs of culture time with the best 
results for ILs with longer and double chain as C16MImCl and (C10)2MImCl, respectively 
(Figure 6A). An increasing of cell proliferation over longer culture time for unloaded-
CaP and ILs-loaded CaP was obtained, however unloaded-CaP shows higher values than 
loaded-CaP (Figure 6B). 
 
5.4.2 Alkaline Phosphatase and Osteocalcin expression as markers of osteogenic 
differentiation 
ILs-loaded CaP showed higher value on ALP expression than CaP at 3 and 7 days. In the 
meantime, a decrease in ALP value at 14 and 21 days was observed (Figure 7A). The 
later osteogenic marker as Osteocalcin (OCN) was also analysed. The results 
demonstrated that ILs-loaded CaP showed higher values of OCN than unloaded-CaP, 
particularly, the highest values were observed for C16MImCl and (C10)2MImCl-loaded CaP 
at day14. C4MImCl(2wt%)-loaded CaP showed OCN levels comparable to unloaded CaP; 
this behaviour might be due to an greater increase in cell proliferation and extra culture 
time for the two materials as compared to each other (Figure 7B). 
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5.5 Effect of IL-loaded CaP gels on inflammation response 
To assess the effect of gel materials on inflammatory response through oxidative stress 
and anti-inflammatory cytokine, investigations were performed. LPS (1μg/ml for 72h) 
stimulation caused a significant increase on nitrite level production with highest values 
for unloaded-CaP system (Figure 8A). In the meantime, the presence of ILs of short and 
long chain significantly reduces the nitrites production. The lowest values were obtained 
for CaP loading ILs at 1wt% with short chain (C4 and C10), whereas high values were 
obtained for (C10)2MImCl (2%)-loaded CaP. Moreover, a reduction in ROS levels was 
also observed for all gels compared to LPS stimulation (Figure 8B). The lowest values 
were obtained for CaP loading ILs at 1wt% with short chain (C4 and C10) confirming their 
different behaviour in comparison with the others. The inhibitory effect of the ILs-loaded 
CaP on nitrites and ROS production in LPS-treated hMSCs was combined with an 
increase in IL-10 levels (Figure 8C) for CaP loading C10MImCl and C16MImCl (2wt%). 
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(A)      (B) 
 
 
Figure 6. Cell proliferation at day 1 (A) and 3, 7, 14 and 21 (B) days of cell culture. 
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(A) 
 
 
 
 
 
 
 
 
 
 
 
      
(B) 
 
Figure 7. ALP expression at 3, 7, 14 and 21 days (A) and osteocalcin expression at 14 
and 21 days of cell culture (B). 
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Figure 8. Effects of CaP-ILs plus ionic liquids on anti-inflammatory markers [nitrites 
(A), ROS (B), IL-10 (C) levels]. 
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 Discussion 6.
Infections associated with in vivo implants represent the most severe postsurgical 
problems of medical device implants, including prosthetic joints (i.e. hip, knee and 
shoulder) and fracture fixation [20]. The increasing ageing population and increased 
participation in recreational activities propels growing demands for surgical implantation, 
which is associated with a continuously increasing of number of infections [21]. These 
infections are usually produced by microorganisms, which grow in specific structures, 
known as biofilms [22]. In this case, the pathogenesis of implant-associated infection 
involves interaction between microorganisms, implant and host. Foreign bodies remain 
devoid of microcirculation, which is crucial for host defence and delivery of antibiotics. 
The life within a biofilm represents a basic survival mechanism by which microbes resist 
against external and internal environmental factors, such as antimicrobial agents (i.e. 
silver nanoparticles, antibiotics) and the host’s immune system [23]. Appropriate 
diagnosis of infections associated with implants is an important challenge, and 
recognized infections may not be effectively treated with long-term systemic antibiotic 
therapy [24]. Consequently, postsurgical infections often require additional surgical 
procedures such as debridement, prosthesis removal and re-implantation with increasing 
costs for healthcare systems. The systemic antibiotic treatment increases several issues, 
such as systemic toxicity, low efficiency and need for hospitalization [25, 26]. Given this 
context, extended delivery of antimicrobial agents at the site of implantation is highly 
desirable in order to offer high local antibiotic concentration without systemic toxicity 
and thereby prevent postoperative, implant-associated infections. However, microbial 
biofilms are resistant to a variety of antimicrobial agents, including antibiotics and  
industrial antiseptic biocides. On this basis, in this work the possibility to load Ionic 
Liquids (ILs) in calcium phosphate (CaPs) materials at different percentages (1-2wt%) 
and at different alkyl chain lengths (starting from 4 to 16 carbon atoms at single chain 
and 10carbon atoms at double chain) to obtaining antimicrobial and antifungal 
biocomposites was demonstrated. CaP based materials were chosen because they are 
commonly used in orthopaedic and dental surgery as bone void fillers [27]. In particular, 
Hydroxyapatite (HAP), β-tricalcium phosphate (β-TCP) and biphasic calcium phosphate 
(BCP) represent typical examples of CaPs minerals, which are known to integrate well 
with surrounding bone tissue and facilitate bone tissue growth [28]. Moreover, CaPs are 
generally considered to play a structural role in bone regeneration, acting as a barrier to 
soft tissue infiltration and as facilitators of the onset and growth of new bone tissue. On 
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the other hand, all CaP-based compounds are, to different extents, degradable in the 
physiological environment. However, no conclusive evidence exists yet to explain 
exactly how free calcium (Ca
2+
) or inorganic phosphate ions released from these 
materials play a direct role in the biological responses to these materials [29]. This is in a 
part because the process of dissolution/reprecipitation of a ceramic is not dependent on 
one, but on a multitude of material characteristics, including CaP crystal phase and 
specific surface area. In our work, the loading of ILs at different chain lengths during 
hydroxyapatite sol-gel synthesis had some effect on morphology and nanoparticles sizes. 
In fact, morphological investigations by TEM analysis (Fig.1) demonstrated the presence 
of crystal nanoparticles and nanoplates, which increases in size by increasing ILs chain 
length. The nanoplates are typical of the monetite phase, which was determined by XRD 
analysis (Fig.2). X-ray results demonstrate an increasing amount of monetite amount 
when alkyl chain is increased that causes a reduction of HA phase. Furthermore, the 
alkyl-chain length and the amount of ILs affect cellular behaviour in terms of osteogenic 
differentiation. Osteogenic differentiation of the cells was first assessed using ALP 
enzyme activity. ALP is considered an early marker of osteogenesis that is known for its 
ability to convert extracellular pyrophosphate, a mineralization inhibitor, into inorganic 
phosphate [30]. To evaluate the effect of monetite on early and later osteogenic 
differentiation, we have also plotted the ALP and OCN markers concentrations (ng/mL) 
in function of monetite %. In this case, it has been evaluated how ALP and OCN 
expressions change in relation to monetite % for different biocomposites at different alkyl 
chain lengths and ILs amounts (Figure S1-S3). In detail, at an early time interval (day 3) 
a correlation between alkyl-chain length and amount of ILs with ALP expression was not 
observed (Supplementary Information Figure S1). In Fig. S2 (Supplementary 
Information) we reported the ALP expression, monitored on all the samples after 14 days 
of incubation, for ILS amounts of 1% (empty circles) and 2% (full circles). We reported 
the same plots twice as, on the left, we wanted to show how, at day 14, the ALP 
expression increases with the alkyl-chain (red arrows); while on the right Fig. S2 shows 
that the ALP expression increases with the ILs amount with the exception of CaP_C4 
(yellow arrow), CaP_C10 (blue arrow) and CaP_(C10)2 (red arrow) biocomposites, which 
show lower ALP levels. However the drop after day 14 is possibly reflective of the cells 
entering a matrix maturation phase and mineralization, in fact these biocomposites show 
an increase in OCN expression at the same point in time (Supplementary Information 
Figure S3). The linear correlation of OCN expression and alkyl-chain length and ILs 
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amount was observed at day 21, where a stable material was obtained. The effect of ILs 
on hMSC osteogenic differentiation was due to the presence of monetite phase in 
synthesized biocomposites. Danoux et al, [31] have reported that monetite nanoplates 
show osteoinductive properties due to higher surface area and roughness than HA nano-
crystals. Di Silvio et al [32] demonstrated the possibility of producing monetite-based 
scaffolds able to facilitate differentiation of hMSCs towards osteogenic differentiation in 
the absence of external additives, that is, non-osteogenic-conditioned medium. 
Furthermore, the antimicrobial studies confirmed the antifungal activity (C. Albicans, C. 
Tropicalis) of the biocomposites with C10MImCl, C16MImCl and (C10)2MImCl. In the 
meantime, results on the antibacterial properties of the materials suggested that the best 
response on bacteria proliferation inhibition was obtained with (C10)2MImCl based 
biomaterial on E. Coli. The bone implant in the osteoporotic area can also induce an 
inflammatory response associated with microorganism infections. Therefore, the aim of 
this work was to study the effect of these biocomposites on inflammation processes using 
in vitro experimental models. We evaluated the effect on two different markers of oxide 
stress, such as nitrite levels and ROS production and quantification of anti-inflammatory 
cytokines, such as IL-10 levels. Results suggested that all the system composed of 
calcium phosphate and ionic liquids reduced nitrite levels when compared to the usage of 
calcium phosphate alone. Moreover, the materials also induced a reduction in ROS levels, 
such as the control plate. This anti-inflammatory effect was confirmed by the evaluation 
of IL-10 level quantification, which was higher for calcium phosphate alone compared to 
lower levels of LPS. At the same time, the materials induced a much better expression of 
IL-10 than the control plate. 
 
 Conclusion 7.
In the present study, our aim was to evaluate the effect of CaP-ILs injectable materials 
(which could be defined as multitasking) on the osteogenesis process. Indeed, these 
materials provide a positive response to hMSC and microorganisms proliferation. 
Furthermore, as systems composed of calcium phosphate and ionic liquids can be 
synthesized at room temperature with the sol-gel approach, it is therefore, possible to 
conclude that ionic liquid-hydroxyapatite based biocomposites possess antimicrobial, 
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osteoinductive and anti-inflammatory properties with better performance obtained in 
systems composed of longer alkyl chain lengths. 
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Supplementary Information 
 
 
 
 
 
 
 
 
 
Figure S1: Evaluation of ALP expression at day 3 demonstrated by increasing n-alkyl 
chain length. ALP does not increase. However higher levels of ALP than compared to 
CaP alone were observed in presence of C4, C10 and (C10)2 at 1 % of ILs. In contrast to 
CaP plus ILs, the highest values of ALP were observed in presence of C16.  
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(A) 
 
(B) 
 
 
Figure S2: The evaluation of ALP expression showed that by increasing n-alkyl chain 
length (C4, C10 and C16) ALP values increase (A). Moreover, at day 14 ALP for C16 
increases not only  with the alkyl chain but also with increasing the amount of ILs (2%) 
(B). Meanwhile for C4, C10 and (C10)2 increasing ILs decreases the amount of ALP 
expressions. 
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(A) 
 
 
(B) 
 
 
Figure S3: Evaluation of Osteocalcin (OCN) production after 21 days of cell culture. 
Demonstrated that increases in n-alkyl chain length increases OCN values.  (A). In 
contrast at day 14 OCN levels increase when the ILs amount increases as well (2%) 
only for C10 and C (10)2 (B). 
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CHAPTER IV 
 
Conclusions and Future Perspectives 
Tissue engineering strategies are based on the combination of cells, bioactive factors and 
biomaterials for tissue regeneration. Osteoporosis, the most common bone pathology, is 
characterised by an imbalance between bone resorption and formation resulting in a high 
risk of fractures. Thus, the aim of the present thesis was to evaluate the in vitro effect of 
different biomaterials on bone regeneration in terms of osteogenesis and inhibition of 
inflammation and infection as related to osteoporosis processes in order to identify new 
alternatives to conventional osteoporosis treatments that cause several systemic side 
effects. Biological studies on these materials leads to the conclusion that our scaffolds 
may be a source of a new kind of implants with a potential therapeutic activity in bone 
defects derived from pathological bone conditions such as osteoporosis. In fact, the 
materials proved capable of regenerating damaged bone tissue. The present study 
concerned the bioactivation and the development of two different systems: chitosan-
based scaffolds bioactivated with organic and inorganic signals and injectable CaP based 
materials combined with ionic liquids, at different carbon chain lengths. Results on CS-
based scaffolds, obtained through biomimetic treatments, suggested the possibility of 
using these materials for bone tissue regeneration thanks to their high interconnectivity, 
homogeneous structure, and pores with different dimensions from 20 µm to 300 µm. The 
presence of bioactive signals allows for osteoinductive effect on hMSC, making chitosan-
based scaffolds a promising material for bone tissue regeneration. Indeed, bioactive and 
biocompatible chitosan scaffolds promote proliferation and induce differentiation of 
hMSC thus representing a new clinical prospect in the field of biomedical applications. 
Furthermore, the combination of chitosan-based scaffolds with different bioactive signals 
(inorganic and organic) leads to the development of a new class of multifunctional 
biomaterials in tissue engineering field. Besides, the ability of chitosan-based materials to 
inhibit inflammatory response and promote the angiogenesis process emphasizes the 
possibility of making use of this scaffold material as promising candidate for bone 
regeneration.  In conclusion, the present investigations on chitosan materials, not only 
reveal new and interesting opportunities to obtain substitutes for a complete bone tissue 
regeneration but they also underline their preliminary effect on the angiogenesis process. 
Beginning with this evidence, future perspectives could continue the study of 
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bioactivated-based scaffolds in an in vitro co-culture system, composed of osteoblast-like 
phenotype and endothelial cells, in order to mimic in vivo conditions. Meanwhile, the 
second part of this thesis was based on the synthesis of injectable ionic liquids-
hydroxyapatite (CaP-ILs) based biocomposites by sol-gel approach. They represent an 
advantageous method that allows operating at room temperature while fabricating 
biocomposites with high levels of osteoinductivity, excellent antimicrobial activity, 
bioactivity and full injectability. In other words, our interest was to investigate the effect 
of these biocomposites on cellular behaviour in terms of proliferation and osteogenic 
differentiation. Materials showed high biocompatibility without cytotoxic effect and a 
positive effect on cell attachment. Furthermore, results demonstrated that multitasking 
CaP-ILs gels have a simultaneous opposite responses toward hMSC and microorganisms 
proliferation inhibition. Particularly, data showed that the loading of ILs at different chain 
lengths during hydroxyapatite sol-gel synthesis had effect on morphology and 
nanoparticle sizes with the formation of monetite phase. The presence of monetite 
increases with the alkyl chain length had effect on biological properties. In fact, the best 
performances, in terms of early and late osteogenic differentiation of hMSC were 
obtained in the presence of systems at longer alkyl chain lengths CaP_C16 and 
CaP_(C10)2. Hence, CaP-ILs systems appear to be very useful for regenerating bone 
tissue and reducing microbial infections associated with bone implants. In conclusion, all 
results obtained by testing chitosan-based scaffolds and injectable CaP-ILs systems in in 
vitro models of remodelling bone tissue make it a possibility to translate these preclinical 
results to future clinical trials. 
